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ABSTRACT 
 
 
For the past three decades, advances in the treatment of central nervous system 
(CNS) tumors such as malignant glioma have only been modest. One particular challenge 
facing treatment of brain tumors is the delivery of therapeutically effective concentrations 
of anti-cancer agents to the target site in the brain. The sanctuary of the brain is protected 
by several barrier systems such as the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (BCSFB). These barriers restrict the passage of anti-cancer 
drugs into the brain via several protective mechanisms. 
 
In the present study, we used cerebral microdialysis sampling, a technique for 
sampling unbound molecules in brain extracellular fluid (ECF) via semi-permeable 
probe, to assess the role of murine ATP Binding Cassette (ABC) transporters Bcrp1, 
P-gp, and Mrp4 in CNS penetration of molecularly targeted agents under investigation 
for treatment of malignant glioma. We choose the specific inhibitor of epidermal growth 
factor receptor (EGFR), erlotinib (TarcevaTM), and the specific inhibitor of platelet-
derived growth factor receptor (PDGFR), crenolanib, as examples of tyrosine kinase 
inhibitors currently tested for treatment of malignant glioma. Given the poor 
microdialysis probe recovery of these lipophilic molecules, we enhanced their recovery 
by including an affinity-based trapping agent, 10% hydroxypropyl-betacyclodextrin 
(HPBCD), in the perfusate. Using this technique, we studied erlotinib and its major 
metabolite, OSI-420, penetration in control and transporter-deficient mice. We showed 
that Bcrp1 is the main efflux transporter preventing erlotinib and OSI-420 penetration in 
mouse brain. Intracellular accumulation studies confirmed the role of BCRP in erlotinib 
and OSI-420 transport. We also characterized the role of solute carrier transporters in 
erlotinib and OSI-420 brain accumulation. Our data show that erlotinib and OSI-420 are 
substrates for members of the SLC22A family of uptake transporters, OAT3 and OCT2. 
 
We then sought to characterize the disposition of tyrosine kinase inhibitors in 
malignant glioma using cerebral microdialysis. We decided to use a transgenic mouse 
model that highly recapitulates several features of the human glioma including tumor 
histology and genetic profiles. However, the bregma commonly used as a reference point 
to place microdialysis cannula does not appear on images derived by magnetic resonance 
imaging (MRI), the imaging method used to identify the size and location of the 
spontaneously arising tumors. Thus, we realized that a new technique to implant the 
microdialysis guide cannula would be necessary. Using angiography studies of mouse 
brain vasculature and T2-weighted MRI, we identified the intersection of the midline 
suture and the rostral rhinal vein on the mouse brain surface as a reference point for 
implanting the microdialysis cannula. This point correlated with the intersection between 
the midline and the olfactory bulb/frontal lobe border visualized on T2-weighted MRI. 
Our method allowed for accurate placement of microdialysis cannula in tumors 
developing in several regions of the mouse brain. 
 
While cerebral microdialysis is commonly used to monitor CNS disposition of 
single anti-cancer drug at a time, the feasibility of simultaneous sampling of multiple 
 vi 
anti-cancer agents via cerebral microdialysis has not been reported. However, combining 
anti-cancer drugs represents a promising strategy for treatment of resistant CNS tumors, 
as malignant glioma. Given the role played by EGFR and PDGFR in providing multiple 
inputs for sustaining glioma cell survival and proliferation, combining inhibitors of 
EGFR (erlotinib) and PDGFR (crenolanib) represents a promising treatment strategy for 
these tumors. The goal of our last set of studies was to optimize microdialysis conditions 
to sample crenolanib and erlotinib as single agents or in combination from tumor ECF in 
a xenograft mouse model of glioma. By including 10% HPBCD in the perfusate, probe 
recovery of both erlotinib and crenolanib was significantly increased. To estimate probe 
recovery we used the zero-flow rate (ZFR) which estimated stock concentrations with 
15% accuracy. The enhanced recovery achieved by including HPBCD coupled with 
sensitive analytical techniques allowed us to determine crenolanib and erlotinib 
penetration in tumor ECF under steady state conditions. No significant differences were 
observed in drug penetration between groups treated with single agent or those treated 
with both drugs. 
 
In conclusion, we developed techniques to improve microdialysis probe recovery 
of lipophilic agents administered as single agents or in combination. We also developed 
an MRI-guided method to implant microdialysis cannula in a spontaneous glioma murine 
model. These techniques enhance our ability to perform microdialysis studies on a large 
spectrum of anti-cancer agents in clinically relevant murine models. Using the developed 
techniques, we identified efflux and uptake transporters that regulate erlotinib CNS 
disposition. We evaluated the extent of erlotinib and crenolanib penetration in malignant 
glioma models. Our results shed more light on the extent of tumor penetration of two 
tyrosine kinase inhibitors currently being tested for treatment of malignant glioma. 
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CHAPTER 1.    INTRODUCTION 
 
 
1.1. INTRODUCTION OF MALIGNANT GLIOMA 
 
 
1.1.1. Incidence of malignant glioma in adult and pediatric populations 
 
Malignant gliomas are a heterogeneous group of tumors that represents about 
70% of adult central nervous system (CNS) tumors (Porter et al., 2010). Approximately 
75% of adult gliomas are malignant and can be categorized in two histological 
subclasses: anaplastic astrocytoma (AA; World Health Organization WHO grade III) and 
glioblastoma multiforme (GBM; WHO grade IV). AA and GBM are collectively referred 
to as high-grade gliomas (Fuller, 2008). According to the central brain tumor registry of 
the United States (CBTRUS), more than 15,000 adult patients are diagnosed with 
malignant gliomas each year (CBTRUS, 2010). Conversely, malignant childhood gliomas 
are less common than their adult counterparts, comprising only 15-20% of all childhood 
CNS tumors (Broniscer and Gajjar, 2004). The reported incidence of malignant glioma in 
both adults and pediatric populations has increased over the past 30 years, partially due to 
improved diagnosis with novel imaging modalities such as computed tomography (CT) 
and magnetic resonance imaging (MRI) (Legler et al., 1999; Smith et al., 1998). 
 
The anatomical location of these tumors differs in adults and children. In adults, 
the majority of malignant gliomas develop in the subcortical white matter of the cerebral 
lobes (86%) while the rest develops either in the deep structures of the cerebrum, the 
ventricles, or in the cerebellum (Larjavaara et al., 2007). On the other hand, pediatric 
gliomas arise from the supratentorial hemispheres or from the pons with the later known 
as diffuse brainstem glioma. Supratentorial tumors represent 6-12% of all pediatric 
primary CNS tumors while diffuse brainstem glioma accounts for 3-9% (Broniscer and 
Gajjar, 2004). 
 
 
1.1.2. Pathological features of malignant glioma 
 
Depending on the course of the disease, malignant gliomas can be categorized 
into primary tumors that develop de novo in the brain with no prior tumor lesion, or 
secondary tumors that progress from a low grade to a higher grade astrocytoma (Furnari 
et al., 2007). Both adult and pediatric glioma arise predominantly de novo while 
secondary tumors are rare (Broniscer et al., 2007a; Furnari et al., 2007; Phuphanich et al., 
1984; Wen and Kesari, 2008). 
 
Malignant gliomas are characterized by their histological heterogeneity. AA 
presents clinically with abnormally high mitotic activity and increased cellularity. GBM 
also displays similar, or higher, hypercellularity in addition to the highly hypoxic nature 
of these tumors (Fuller, 2008). GBM is distinguished from AA via two characteristic 
features. First, GBM tumors exhibit micronecrotic foci surrounded with pseudopalisading 
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cells (Rong et al., 2006). The second characteristic feature of GBM is its high angiogenic 
propensity and intense microvascular hyperplasia (Fuller, 2008; Miyagami and 
Katayama, 2005). This hyperplastic vasculature develops in response to pro-angiogenic 
growth factors, such as vascular endothelial growth factor (VEGF), that induce 
endothelial cell survival, proliferation, and migration (Plate et al., 1994). These 
microvessels are structurally and functionally immature, which may contribute to poor 
tumor oxygenation and hypoxic microenvironment (Miyagami and Katayama, 2005). The 
formation of new blood vessels is crucial for glioma development and progression. This 
was supported by reports showing that high degree of microvascular proliferation 
correlates with low overall survival in adult glioma patients (Bello et al., 2004; Cheng et 
al., 1996; Leon et al., 1996). 
 
An important histological feature of high-grade gliomas is the highly invasive 
propensity of glioma cells as they metastasize and invade either along endothelial cells or 
more frequently through the brain parenchyma. This diffuse infiltrative phenotype is 
referred to as gliomatosis cerebri (Bendszus et al., 2000). Because of this infiltrative 
growth pattern, complete surgical resection of malignant glioma is not possible, and local 
tumor recurrence is inevitable (Giese et al., 2003). 
 
 
1.1.3. Genetic and molecular alterations characteristic of malignant glioma 
 
In the past five years, studies conducting comprehensive genomic and protein 
expression profiling of adult and pediatric malignant glioma revealed differences in gene 
copy number alterations and transcriptional profiles (Parsons et al., 2008; Paugh et al., 
2010a; TCGA, 2008) (Table 1-1). These studies revealed that the function of several 
tumor suppressor pathways such as P53 and retinoblastoma (Rb) is commonly mutated or 
deleted in both adult and pediatric gliomas (Newcomb et al., 2000; Pollack et al., 2001; 
Suri et al., 2009; TCGA, 2008). Alteration of multiple receptor tyrosine kinases (RTKs) 
signaling pathways is another frequent genetic finding in malignant gliomas (Parsons et 
al., 2008; Paugh et al., 2010a; Stommel et al., 2007; TCGA, 2008). RTKs are a family of 
cell surface receptors that can be activated by extracellular ligands. Upon activation, 
RTKs phosphorylate tyrosine residues on several target proteins resulting in their 
activation (Fan and Weiss, 2010; Robinson et al., 2000). The signal initiated by RTKs is 
then transduced and amplified through intracellular downstream pro-survival signaling 
cascades, such as the phosphatidyl inositol 3-kinase/Akt (PI3K/Akt) pathway or the 
mitogen-activated protein kinase (MAPK) pathway, leading to increased tumor cell 
survival, migration, and invasiveness (Fan and Weiss, 2010; Ren et al., 2007) (Figure 
1-1). RTKs shown to play a role in the development, progression, or therapeutic 
resistance of malignant glioma include the epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor 
receptor (VEGFR) (Ayuso-Sacido et al., 2010; Paugh et al., 2010a; Raymond et al., 2000; 
Squatrito and Holland, 2011). 
 
About half of adult glioma cases exhibit mutation or amplification in EGFR 
(TCGA, 2008). Deletion or mutation of the phosphate and tensin homolog tumor  
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Table 1-1. Summary for important genetic alteration in adult and pediatric 
malignant glioma 
 
Gene Alteration in adult glioma 
patients 
Alteration in pediatric glioma 
patients 
EGFR Amplification (25%) (Parsons et 
al., 2008; TCGA, 2008) 
Mutation (3.3%) (TCGA, 2008) 
Mutation and amplification 
(17.5%) (TCGA, 2008) 
Amplification (rare) (0-7%) 
(Bredel et al., 1999; Paugh et al., 
2010a; Pollack et al., 2006; Sung 
et al., 2000; Suri et al., 2009) 
 
PDGFRA Amplification (13%)(TCGA, 
2008) 
Amplification (14%) (Paugh et 
al., 2010a) 
c-MET Amplification (4%)(TCGA, 
2008) 
Amplification (rare in GBM 3% 
but more common in diffuse 
intrinsic pontine glioma 26%) 
(Paugh et al., 2010a) 
PTEN Mutation, homozygous deletion 
(36%) (Parsons et al., 2008; 
TCGA, 2008) 
Deletion (rare) (0-5%) (Pollack et 
al., 2006; Suri et al., 2009) 
P53 Pathway TP53: Mutation, homozygous 
deletion (35%) (TCGA, 2008) 
Genes that regulate p53 stability: 
MDM2, amplified in 14%, 
MDM4, amplified in 7% 
CDKN2A, homozygous deletion 
or mutation in 52% 
Collectively, this pathway is 
targeted in 87% of cases (TCGA, 
2008) 
Mutation (34%)(Pollack et al., 
2001) 
RB Pathway RB1: Mutation, homozygous 
deletion (11%)(TCGA, 2008) 
Genes that regulate Rb activity: 
CDKN2A, deletion or mutation 
in 52%  
CDKN2B, deletion in 47% 
Collectively, this pathway is 
altered in 78% of cases 
CDKN2A, homozygous deletion 
(10%) (Newcomb et al., 2000) 
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Figure 1-1. Schematic presentation of signaling pathways targeted by molecular therapies in malignant glioma 
 
The diagram illustrates pathways that are activated upon RTK activation. PDGFR, EGFR, and VEGFR activation share 
common intracellular effectors. Arrowheads indicate signal transduction while a blunted end indicates inhibition of a target. 
 
Source: Adapted by permission from Springer. Mercer RW et al. (2009) Targeted Therapies for Malignant Glioma Progress 
and Potential. BioDrugs 23:25-35. 
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suppressor gene (PTEN), the major inhibitor of PI3K/Akt signaling pathway is found in 
36% of these tumors (TCGA, 2008). In contrast, pediatric glioma cases rarely exhibit 
EGFR gene amplification or PTEN gene deletion or mutation (0-5%) (Paugh et al., 
2010a; Pollack et al., 2006; Sung et al., 2000; Suri et al., 2009). Despite the low 
frequency of EGFR amplifications in childhood glioma, EGFR protein overexpression is 
observed in up to 85% of the cases (Bredel et al., 1999; Gilbertson et al., 2003; Pollack et 
al., 2006; Thorarinsdottir et al., 2008). 
 
In pediatric gliomas, platelet-derived growth factor alpha (PDGFRA) is the 
predominant target of focal amplification (Paugh et al., 2010a). The extent of PDGFRα 
activation, measured by the receptor phosphorylation of several tyrosine residues, is 
significantly associated with the malignant histology of childhood gliomas 
(Thorarinsdottir et al., 2008). Other receptor tyrosine kinases, such as c-MET, may be 
altered in adult and pediatric gliomas (Paugh et al., 2010a; TCGA, 2008). The different 
frequencies of genetic alterations between adult and pediatric gliomas reflects the 
complexity and heterogeneity of these tumors and indicates the need for molecularly 
targeted therapies directed towards the aberrant signaling pathways in individual tumors. 
 
The activation status of critical glioma survival pathways, such as PI3K/Akt, is 
determined by redundant inputs from multiple receptor tyrosine kinases (RTKs) such as 
EGFR, PDGFR, and c-MET. The signals provided by these RTKs can be either used 
simultaneously or sequentially by glioma cells to maintain an active downstream 
PI3K/Akt signaling and thus inhibiting PI3K/Akt signaling may require targeting 
multiple RTKs (Stommel et al., 2007). 
 
 
1.1.4. Current approaches for treatment of malignant glioma 
 
The prognosis and clinical outcome for AA patients is better than those diagnosed 
with GBM (Broniscer et al., 2005; Finlay et al., 1995; Rutten et al., 1981). Despite 
aggressive treatment modalities, including surgical resection, radiation, and 
chemotherapy, the median overall survival of patients with newly diagnosed GBM is less 
than 4 years for children and 1.5 years for adults (Minniti et al., 2008; Song et al., 2010; 
Stupp et al., 2005). The infiltrative nature of malignant glioma allows these tumors to 
invade and metastasize through the brain parenchyma. Ultimately, this invasive 
propensity leads to failure of surgical resection to achieve complete tumor removal 
(Amberger-Murphy, 2003; Giese et al., 2003). 
 
For adult patients newly diagnosed with malignant glioma, the standard treatment 
regimen for adults is radiotherapy (2 Gray per day 5 days per week for 6 weeks, for a 
total of 60 Gray), plus continuous daily administration of temozolomide, a DNA 
alkylating agent. This is followed by six cycles of temozolomide (150 to 200 mg per 
square meter for 5 days during each 28-day cycle). This regimen modestly improved the 
median survival of GBM patients to 14.6 months as compared to 12.1 months with 
radiotherapy alone (Stupp et al., 2007; Stupp et al., 2005). 
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Given the highly vascular nature of malignant glioma, angiogenesis inhibitors, 
especially those targeting VEGF signaling, have been used alone or in combination with 
chemotherapeutic agents for the treatment of adult recurrent glioblastoma. A multi-center 
phase II study reported a notable improvement of the 6-month progression-free survival 
in patients with recurrent GBM treated with bevacizumab, a VEGF monoclonal antibody, 
when compared to historical controls treated with irinotecan alone (Friedman et al., 
2009). The impressive results reported in this study led to the accelerated US Food and 
Drug Administration approval of bevacizumab for treatment of adult patients with 
recurrent glioblastoma. 
 
In contrast to their adult counterparts, pediatric glioma patients showed poor 
response to the standard of care of the adult population. The administration of 
temozolomide after radiation therapy failed to improve the poor prognosis of children 
with malignant glioma (Broniscer and Gajjar, 2004; Broniscer et al., 2005). Further, 
disappointing results were reported in trials using bevacizumab and irinotecan in 
treatment of children with recurrent malignant glioma (Gururangan et al., 2010). For 
pediatric glioma patients, maximum safe surgical resection and radiation therapy is the 
mainstay of treatment. The striking differences between the pediatric and adult 
populations in their response to several therapeutic regimens, despite their histological 
similarities, support the use of regimens that target specific pathways altered in each 
tumor (Broniscer and Gajjar, 2004). 
 
 
1.1.5. Emerging treatments for malignant glioma 
 
The advances in our understanding of the genetic alterations of these tumors allow 
for the identification of molecular targets that are important for tumor survival and 
progression. Aberrant signaling through RTKs such as EGFR, PDGFRα, and VEGFR 
results in activation of downstream effectors that promote cellular proliferation, survival, 
invasiveness, and inhibits apoptosis of glioma cells (Ayuso-Sacido et al., 2010; Hatanpaa 
et al., 2010; Sharma et al., 2011). Thus, inhibiting these pathways represent a reasonable 
therapeutic strategy in attempts to inhibit tumor growth. 
 
 
1.1.5.1. Inhibitors of EGFR pathway 
 
Alteration of the EGFR signaling pathway is a common feature in adult glioma in 
the form of gene amplification or mutation (TCGA, 2008), and in pediatric glioma in the 
form of protein overexpression (Bredel et al., 1999; Gilbertson et al., 2003; Pollack et al., 
2006; Thorarinsdottir et al., 2008). These findings make EGFR an attractive target in the 
management of malignant glioma. 
 
Gefitinib (Iressa, Astra Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals) are 
both quinazolin-4-amine derivatives with specific and potent inhibitory activity against 
EGFR. Both gefitinib and erlotinib competitively bind to the cytoplasmic ATP-binding 
domain of EGFR and inhibits its tyrosine kinase activity. This prevents EGFR 
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phosphorylation and interrupts its downstream signaling cascade (Raymond et al., 2000). 
In vitro, erlotinib was shown to suppress anchorage-independent growth and induce 
apoptosis in glioma cell lines (Halatsch et al., 2004).Only erlotinib, not gefitinib, can 
inhibit the most common type of EGFR mutation, EGFRvIII, which lacks a portion of the 
extracellular ligand binding domain rendering EGFR constitutively active (Heimberger et 
al., 2002; Peereboom et al., 2010). 
 
EGFR inhibitors were shown to reduce tumor growth and prolong survival in 
subcutaneous xenograft models of high-grade glioma (Ciardiello et al., 2001; Heimberger 
et al., 2002). However, neither gefitinib nor erlotinib showed clinical benefit in 
improving the overall survival in adult or pediatric patients with high-grade glioma 
(Geoerger et al., 2011; Peereboom et al., 2010; Prados et al., 2009; Raizer et al., 2010b; 
Reardon et al., 2006; Rich et al., 2004; van den Bent et al., 2009a).This might be 
explained by previous reports indicating that targeting EGFR only is insufficient for 
inhibiting downstream PI3K/Akt signaling and that more effective therapy may require 
targeting of multiple RTKs (Stommel et al., 2007). 
 
 
1.1.5.2. Inhibitors of PDGFR pathway 
 
The two isoforms PDGF-A and B homo or hetero-dimerize, bind to, and induce the 
activation of PDGFR α or β. Activated PDGFRα or PDGFRβ then activate PI3K/Akt and 
MAPK pathways (Liu et al., 2011). PDGFRα or β are commonly overexpressed in 
glioma (Guha et al., 1995; Liang et al., 2008; Mauro et al., 1991; Nister et al., 1991; 
Thorarinsdottir et al., 2008) and are thought to play an important role in tumor 
invasiveness and angiogenesis (Pietras et al., 2003; Thorarinsdottir et al., 2008). 
 
Imatinib (Gleevec, Novartis) is an RTK inhibitor that targets Bcr-Abl and c-kit. 
Imatinib also inhibits PDGFR activation though at concentrations higher than that 
required for Bcr-Abl and c-kit inhibition (Mahboobi et al., 2008). Imatinib showed 
promising results in xenografts derived from the human glioma cell lines U343 and 
U87-MG. In these studies, oral administration of imatinib prolonged the survival of 
subcutaneous xenograft mouse models with PDGFR-expressing tumors (Kilic et al., 
2000). The excitement resulting from these preclinical data faded when disappointing 
results were reported in phase II studies in recurrent glioma patients. The reports showed 
that imatinib failed to prolong the 6 months progression free survival of recurrent glioma 
patients (Raymond et al., 2008; Wen et al., 2006). Furthermore, a Phase III study 
comparing the efficacy of the combination of imatinib and adjuvant chemotherapy versus 
chemotherapy alone in heavily pretreated malignant glioma patients showed similar 
median progression free survival in both treatment arms which indicates limited clinical 
benefit of the combination (Dresemann et al., 2010). 
 
Reports showing limited CNS penetration of imatinib, together with its low potency 
and lack of specificity for PDGFR inhibition, raised some questions on whether imatinib 
is a suitable drug for treatment of malignant glioma and suggested the need for more 
specific and potent PDGFR inhibitors with better CNS penetration profiles (Mahboobi et 
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al., 2008; Neville et al., 2004). Fortunately, specific inhibitors of the PDGFR pathway, 
such as crenolanib, are available (AROG Pharmaceuticals, LLC). Crenolanib is an orally 
bioavailable, highly specific, and potent PDGFR inhibitor that targets both α and β 
receptor types (Lewis et al., 2009). Crenolanib is more than 100-fold more selective 
towards PDGFR than other kinases, such as c-KIT, VEGFR-2, and EGFR (Lewis et al., 
2009). Crenolanib (50 mg/kg twice daily) resulted in 47% inhibition of tumor growth in 
U87-MG human glioma subcutaneous xenografts (AROG Pharmaceuticals, LLC, 
Investigator’s Brochure Crenolanib Besylate March 2011). To our knowledge, crenolanib 
CNS penetration has not been reported to date. Currently, crenolanib is undergoing phase 
I trials in children and phase II trials in adult patients with malignant glioma. 
 
 
1.1.5.3. Inhibitors of VEGFR pathway 
 
The development of neovasculature, angiogenesis, is an important process for the 
growth and invasiveness of malignant glioma. The high angiogenic capacity of glioma is 
primarily mediated by VEGF although other proangiogenic factors, such as PDGF and 
fibroblast growth factor (FGF), can also contribute (Guo et al., 2003; Plate et al., 1992; 
Schmidt et al., 1999). VEGF binds to its receptors, mainly VEGFR-2, on tumor vessels 
resulting in increased vascular permeability and enhanced endothelial cell proliferation, 
survival, and migration. Distinct structural and functional abnormalities differentiate the 
newly formed tumor vessels from normal vessels (Plate et al., 1992). Tumor endothelial 
cells are tortuous with large fenestrations, abnormal basement membrane, and reduced 
pericyte coverage (Jain, 2005; Morikawa et al., 2002). Thus, despite the increased 
microvessel density in glioma, the blood flow in these vessels is heterogeneous and 
sluggish which leads to hypoxia, acidosis, necrosis, and elevated tumor interstitial 
pressure (Fukumura and Jain, 2007; Hanahan and Folkman, 1996; Jain, 2001; 2005). 
 
Given the highly angiogenic nature of malignant glioma, targeting angiogenic 
signaling pathways was shown to be a reasonable therapeutic strategy for these tumors 
(Batchelor et al., 2007; Brastianos and Batchelor, 2010; Kamoun et al., 2009). Inhibitors 
of the VEGF signaling pathway are the most clinically developed of the anti-angiogenic 
therapies. Two strategies to target VEGF signaling pathway are currently being tested; 
the first is targeting the ligand, VEGF, using VEGF monoclonal antibodies such as 
bevacizumab (Avastin, Genentech-Roche), and the second is targeting the VEGF receptor 
expressed on capillary endothelial cells, VEGFR2 (McMahon, 2000; Reardon et al., 
2011). 
 
Recent findings showed that bevacizumab in combination with irinotecan improved 
the 6 months progression free survival of patients with recurrent GBM to 46% compared 
to 21% with historical controls, indicating potential benefit of anti-angiogenic agents 
(Vredenburgh et al., 2007). More than half the patients on this trial had at least a partial 
radiological response measured by the extent of tumor enhancement on T1-weighted 
MRI scans (Vredenburgh et al., 2007). 
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Several small molecules targeting VEGFR have been developed such as cediranib 
(Recentin, AstraZeneca). Cediranib, a pan inhibitor of VEGFR, successfully increased 
survival and led to vascular normalization and edema alleviation in orthotopic glioma 
mouse models despite continuous tumor enlargement in the cediranib-treated group 
(Kamoun et al., 2009). A similar, though less pronounced effect, was observed upon 
treating these mice with dexamethasone. These findings suggest that the effect observed 
with cediranib treatment is more likely to be associated with edema alleviation than with 
direct anti-tumor effect (Kamoun et al., 2009). In phase II trials for adult patients with 
recurrent glioblastoma, cediranib showed improved 6 months progression free survival 
(26%), though overall survival was similar to historical controls. Tumor vascular 
normalization was rapidly reversed upon interruption of the cediranib regimen (Batchelor 
et al., 2007). 
 
Ultimately, VEGFR pathway inhibitors produced only modest improvement in the 
overall survival in patients with malignant glioma. This raised the question of whether the 
observed improvement in radiological response and progression free survival is due to a 
genuine anti-tumor effect or merely a result of reduced vascular permeability that limits 
tumor enhancement on T1-weighted MRI. Thus, some oncologists advocate 
reconsidering the anti-edematous effect of bevacizumab as an expensive steroid-like 
effect (van den Bent et al., 2009b; Wick et al., 2010). 
 
 
1.1.6. Challenges facing molecularly targeted therapies in malignant glioma 
 
In general, results from molecularly targeted agents in treatment of malignant 
glioma patients have been disappointing despite some encouraging in vitro and 
preclinical data. No major survival advantage has been observed with any of these agents 
in phase II or III trials (Batchelor et al., 2007; Dresemann et al., 2010; Peereboom et al., 
2010; Raizer et al., 2010b; Rich et al., 2004). The failure of these agents may be 
explained by several resistance mechanisms. These include coactivation of multiple 
receptor tyrosine kinases that provide redundant signals to maintain active downstream 
signaling. Coactivation of three or more RTKs that include EGFR, PDGFRα, and c-MET 
was demonstrated in 19/20 glioma cell lines (Stommel et al., 2007). Inhibition of 
downstream PI3K signaling could only be accomplished when all activated receptors 
were targeted while inhibiting single RTK did not affect downstream signaling (Stommel 
et al., 2007; Thaker and Pollack, 2009). Thus, understanding the pathways activated in 
individual patients and simultaneously targeting multiple components of the PI3K 
pathway using combination regimens may provide clinical benefit for patients with 
malignant glioma (Mercer et al., 2009; Stommel et al., 2007; Thaker and Pollack, 2009). 
 
Further, resistance of malignant glioma to some tyrosine kinase inhibitors can be 
explained by the deletion of key tumor suppressor proteins such as PTEN, a genetic 
alteration almost exclusive to adult glioma patients, leading to constitutive receptor-
independent activation of the PI3K/Akt pathway (Mellinghoff et al., 2005). Recently, the 
genetic complexity of these tumors was recently highlighted in microarray studies that 
identified several molecular subclasses of GBM where each of these subclasses responds 
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differently to treatment indicating that malignant gliomas are more complex than being 
just a single disease type (Phillips et al., 2006; Verhaak et al., 2010). 
 
The effectiveness of molecularly targeted therapies depends upon achieving 
sufficient concentrations of these agents in the tumor for adequate duration. To induce a 
therapeutic effect, the plasma protein-unbound portion of these agents should access the 
relevant target site within the tumor. The concentration of unbound drug achieved within 
the tumor depends on several factors, which include absorption, distribution, metabolism, 
and elimination (i.e., pharmacokinetics) of the drug, the toxicity associated with its 
administration, the extent of plasma protein binding, and the ability of the drug to cross 
the blood-brain barrier (BBB). The BBB limits tumor penetration of these agents and thus 
may provide plausible explanation for the lack of efficacy of drugs with limited CNS and 
tumor penetration (Tredan et al., 2007; Westerhout et al., 2011). Moreover, the 
distribution of anti-cancer drug throughout the tumor is non-uniform (Jain, 2005). 
Uniform distribution of effective concentration of the anti-cancer drug throughout the 
tumor may allow the anti-cancer agent to encounter more tumor cells and thus improve 
its anti-tumor activity. 
 
 
1.2. BARRIERS AGAINST ANTI-CANCER DRUG CNS PENETRATION 
 
The brain is protected by a dynamic barrier that maintains the stability of the brain 
function by separating the brain from the systemic circulation and hence the name blood-
brain barrier (BBB) (Figure 1-2) (Rubin and Staddon, 1999). The BBB plays an 
important role in protecting the sanctuary of the brain and its normal development from 
circulating toxins and harmful chemicals. As a result, the brain will have limited 
exposure to drugs intended to treat neurological diseases and brain tumors (McCarty, 
2005; Rubin and Staddon, 1999). 
 
The BBB is composed of capillary endothelial cells which are supported by 
pericytes, astrocytes, and microglial cells (McCarty, 2005). These endothelial cells are 
connected to each other by a number of integral membrane proteins such as occludins, 
caludins, and ZO 1-3, forming tight junctions that block the paracellular (between cell) 
transport of xenobiotics including anti-cancer drugs (Figure 1-2) (Kniesel and Wolburg, 
2000; Wolburg and Lippoldt, 2002). To overcome this paracellular impermeability, drugs 
have to pass through the endothelial cells (i.e., trans-cellular route) to reach the brain 
(Pardridge, 1999; Terasaki and Ohtsuki, 2005). 
 
Some drugs with high lipophilicity, low polar surface area, and low molecular 
weight can pass through the transcellular route via passive diffusion. However, several 
transport proteins on the endothelial cells can limit the brain penetration of these 
molecules despite their favorable physicochemical properties (Eros et al., 2002; Mahar 
Doan et al., 2002; McCarty, 2005; Pardridge, 1998; Rubin and Staddon, 1999). Members 
of the ATP-binding cassette (ABC) transporter family are efflux pumps expressed on the 
endothelial cells. These pumps transport molecules across the BBB into the blood against 
their concentration gradient by utilizing energy from ATP hydrolysis (PL and GM, 2003; 
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Figure 1-2. Schematic representation of the capillary endothelial cells that build 
up the BBB 
 
A. Cross-section through a brain capillary. 
 
B. Longitudinal section across the wall of the capillary, with the tight junctions that 
separate the membranes into the luminal (i.e. apical) and abluminal (i.e. basolateral) 
sides. 
 
Source: Reprinted by permission from the American Physiological Society. Hagenbuch B 
et al. (2002) Transport of xenobiotics across the blood-brain barrier. News in 
Physiological Sciences 17:231-234. 
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Terasaki and Hosoya, 1999). ABC transporters known to restrict CNS distribution of 
anti-cancer agents include ABCB1 [MDR1; P-glycoprotein (P-gp)], ABCC1 [multidrug 
resistance-associated protein 1 (MRP1)], ABCC4 (multidrug resistance-associated 
protein 4 (MRP4), and ABCG2 [breast cancer resistance protein (BCRP)] (PL and GM, 
2003; Terasaki and Hosoya, 1999). 
 
Another important family of transporters expressed on endothelial cells is the 
solute carrier (SLC) family of transporters (Koepsell and Endou, 2004). In contrast to the 
ABC transporter family, members of the SLC family do not require ATP for their 
function (Degorter et al., 2011; Hediger et al., 2004). SLC transporters mediate the 
movement of their substrates via several mechanisms, including carrier-mediated (i.e. 
facilitated diffusion), ion coupling, and ion exchange mechanisms (Hediger et al., 2004). 
They are primarily involved in the influx of drugs and endogenous compounds to the 
brain. Previous reports showed CNS expression of several SLC family members where 
they play an important role in drug transport across the BBB (Angeletti et al., 1997; Gao 
et al., 2000; Gao et al., 1999; Lin et al., 2010; Noe et al., 1997; Roberts et al., 2008; 
Urquhart and Kim, 2009; WM, 2003). 
 
Another barrier involved in anti-cancer drug CNS distribution is the blood-
cerebrospinal fluid barrier (BCSFB) (Johanson et al., 2005). This barrier is composed 
mainly of the choroid plexus, a layer of polarized epithelial cells lining the ventricles 
(Redzic and Segal, 2004). The choroid plexus is comprised of two layers, an inner layer 
of endothelial cells and an outer layer of ependymal cells (Redzic and Segal, 2004). 
While endothelial cells of the BCSFB are fenestrated, tight junctions are present between 
the outer ependymal cells (Redzic and Segal, 2004; Zheng et al., 2003). These tight 
junctions restrict the paracellular transport across the choroid plexus (Redzic and Segal, 
2004; Zheng et al., 2003). Thus, to enter the CSF, molecules have to cross the fenestrated 
capillary wall and penetrate the ependymal cells of the choroid plexus. Similar to the 
BBB, drug trafficking across the BCSFB is also controlled by efflux and uptake 
transporters (Kusuhara and Sugiyama, 2004). 
 
Many factors are involved in the transport of drugs across the brain barrier membranes. 
Localization of efflux and uptake transporters either on the apical side of the BBB (facing 
the blood) or the basolateral side (facing the brain) will affect the disposition of their 
substrates in the brain extracellular fluid (ECF) (Figure 1-3) (Shen et al., 2009; 
Westerhout et al., 2011; Zhuang et al., 2006). Likewise, the localization of these 
transporters on the apical side of the choroid plexus epithelia (facing the CSF) or the 
basal side (facing the blood) will impact the translocation of their substrates in the CSF 
(de Lange, 2004; Shen et al., 2009; Wijnholds et al., 2000; Zhuang et al., 2006). In the 
following section, the localization of efflux transporters namely P-glycoprotein (P-gp, 
ABCB1), breast cancer resistance protein (BCRP, ABCG2), and multidrug resistance-
associated protein 4 (MRP4) and their impact on the disposition of their substrates within 
different CNS compartments will be discussed. Furthermore, the expression of solute 
carrier transporters organic anion-transporting polypeptide 1A2 (OATP1A2), organic 
anion transporter 3 (Oat3), and the organic cation transporter 2 (OCT2) will be reviewed.
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Figure 1-3. Schematic representation of the BBB 
 
Brain endothelial cells are surrounded by a basal membrane, astrocyte foot processes, 
and supportive pericytes. Tight junctions in brain capillary endothelial cells prevent 
paracellular transport through the BBB. Transcellular diffusion through the BBB is 
affected by efflux and uptake transporters illustrated in the lower portion of the figure. 
P-gp, BCRP, MRP1, MRP4, and OCT2 are localized on the apical border while Oat3 
is expressed predominantly on the basolateral membrane. Oatp2 is expressed at both 
apical and basolateral borders. 
 
Source: Adapted by permission from the American Association for Cancer Research. 
Deeken J et al. (2007) The Blood-Brain Barrier and Cancer: Transporters, Treatment, 
and Trojan Horses. Clin Cancer Res 13:1663-1674.  
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1.2.1. ATP-Binding Cassette family 
 
 
1.2.1.1. P-glycoprotein (P-gp/ABCB1) 
 
P-gp is the most widely studied of all efflux drug transporters. In humans, P-gp is 
encoded by the MDR1 gene while two genes, Mdr1a and Mdr1b, encode P-gp in the 
rodent brain (Bendayan et al., 2002; Gottesman, 1993; Schinkel et al., 1996). P-gp is 
highly expressed on the luminal side of the capillary endothelial cells of the BBB in 
humans, mice, rats, and dogs (Beaulieu et al., 1997; Cordon-Cardo et al., 1989; Hegmann 
et al., 1992; Thiebaut et al., 1989) (Figure 1-3). It is widely accepted that P-gp plays an 
important role in limiting the accumulation of its substrates in the brain ECF and thus 
conferring resistance to these agents (Nobmann et al., 2001; Pardridge, 2005; Schinkel et 
al., 1995). 
 
Expression of P-gp at the ependymal cells of the choroid plexus has been 
established in humans, mice, and rats by several groups (Daood et al., 2008; Rao et al., 
1999a; b; Zhuang et al., 2006). However, the exact localization of P-gp to either side of 
the choroid plexus is not clear yet. In humans, P-gp is thought to localize apically at the 
BBB (Beaulieu et al., 1997; Daood et al., 2008; Rao et al., 1999a). In rodents, P-gp was 
found to exhibit a granular expression pattern throughout the cytoplasm with enhanced 
expression on the apical side of the choroid plexus (Figure 1-4) (Zhuang et al., 2006). 
Given its localization, P-gp can play an important role in active transport of its substrates 
into the ventricular CSF. This will increase the concentration of P-gp substrates in the 
CSF. Using noninvasive single-photon-emission computed tomography, Rao et al 
showed that CSF levels of the P-gp substrate 99mTc-sestamibi is 100-fold more than that 
in blood (Rao et al., 1999b). Our group showed that accumulation of topotecan, a P-gp 
substrate, was significantly higher in the CSF of wild-type mice compared to mice 
lacking P-gp, i.e. Mdr1a/b-/- (Shen et al., 2009). Collectively, these data indicate an 
important role for P-gp in the blood to CSF transport of its substrates. 
 
Important insights to the function of P-gp were obtained from experiments 
conducted with mouse models lacking either one or both of the P-gp encoding genes, i.e. 
Mdr1a-/- and Mdr1a/1b-/- mice (Schinkel et al., 1994; Schinkel et al., 1995; Wijnholds et 
al., 2000). These models were used to demonstrate the role of P-gp in drug disposition in 
the ECF or the CSF. Schinkel et al showed striking 12-fold higher brain concentrations of 
vinblastine, a P-gp substrate, in ECF of Mdr1a-/- mice compared to wild-type mice 
(Schinkel et al., 1994). These models played an important role in studies that evaluate the 
role of P-gp in restricting CNS penetration of several molecularly targeted agents that are 
currently being tested for treatment of high-grade glioma (Agarwal et al., 2010; Marchetti 
et al., 2008; Poller et al., 2011).  
 
 
15 
 
 
 
Figure 1-4. Schematic representation of the BCSFB 
 
Fenestrated capillaries in the choroid plexus permit free transport of molecules. However, 
tight junctions on the choroid plexus epithelial cells limit paracellular transport.  
The CSF-facing surface of the epithelial cells is called the apical border while that facing 
the blood side is called the basolateral border. The figure illustrates the current view of 
the localization of drug transporters at the choroid plexus epithelial cells. P-gp is 
predominantly located at the apical side and seems to transport into its substrates into the 
CSF. BCRP exhibits similar localization to P-gp. MRP1 and MRP4 are localized on the 
basolateral border and they are thought to mediate transport out of the CSF into the 
blood. Uptake transporters such Oat3 is predominantly expressed on the basolateral 
border. The rodent orthologues Oatp1 and Oatp2 corresponding to human OATP1A2, are 
expressed at the apical membrane of the choroid plexus in case of Oatp1 or at both apical 
and basolateral membranes. 
 
Source: Adapted by permission from the American Association for Cancer Research. 
Deeken J et al. (2007) The Blood-Brain Barrier and Cancer: Transporters, Treatment, 
and Trojan Horses. Clin Cancer Res 13:1663-1674.  
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1.2.1.2. Multi-drug resistance associated proteins (MRPs/ABCC) 
 
The ABCC subfamily of ABC transporters consists of 12 members, nine of them 
(MRP1-9) have been implicated in conferring drug resistance. Of these nine members, 
MRP1 and MRP4 are the most relevant to anti-cancer drugs used in treatment of brain 
tumors. 
 
MRP1 is expressed on the apical side of the capillary endothelial cells forming the 
BBB (Figure 1-3). According to this orientation, MRP1 can limit the penetration of their 
substrates to brain ECF. Mrp1-/- mouse models show higher brain accumulation and 
enhanced sensitivity towards MRP1 substrates such as the topoisomerase II interacting 
agent, etoposide, compared to their wild type counterparts (Lorico et al., 1997; Wijnholds 
et al., 1997). 
 
On the choroid plexus, Mrp1 is expressed on the basolateral side of the 
ependymal cells. This localization, in contrast to P-gp localization, allows the efflux of 
drugs from the CSF into the blood (Figure 1-4). The role of MRP1 in CSF to blood 
transport was confirmed by studies showing 10-fold higher etoposide accumulation in the 
CSF of Mrp1-/- mice (Wijnholds et al., 2000). Given its role on the BBB and the BCSFB, 
Mrp1 can serve as an important detoxification system of the whole brain (de Lange, 
2004). 
 
Similar to Mrp1, MRP4 is expressed on the apical membrane of the endothelial 
cells of the BBB (Figure 1-3) and on the basolateral membrane of the choroid plexus 
(Figure 1-4) (Huai-Yun et al., 1998; Leggas et al., 2004a; Nies et al., 2004; Roberts et 
al., 2008; Zhang et al., 2000). Leggas et al showed increased topotecan brain penetration 
in Mrp4-/- mice compared to wild-type mice indicating a potential role for MRP4 in 
restricting topotecan brain ECF accumulation (Leggas et al., 2004a). Further, MRP4 was 
shown to reduce the intracellular accumulation of the tyrosine kinase inhibitor imatinib in 
MRP4 expressing Saos-2 cells (Hu et al., 2008). This suggests that MRP4 can play an 
important role in disposition of several chemotherapeutic and molecularly targeted 
agents. Further investigation is necessary to elucidate the role of MRP4 in brain transport 
of other molecularly targeted agents. 
 
 
1.2.1.3. Breast cancer resistance protein (BCRP/ABCG2) 
 
Another member of the ABC transporter family was first identified in a breast 
cancer cell line MCF-7/AdrVp and hence named breast cancer resistance protein (BCRP) 
(Doyle et al., 1998). Additional studies showed that BCRP is expressed on the apical side 
of the capillary endothelial cells in humans, rats, and mice brains where it has been 
implicated in brain to blood transport of its substrates (Figure 1-3) (Cooray et al., 2002; 
Hori et al., 2004). On the human choroid plexus, BCRP expression has not been 
extensively studied. However, studies from mouse and rat brain showed apical 
localization on the choroid plexus (Figure 1-4) (Zhuang et al., 2006). This P-gp-like 
localization, suggests that BCRP limits the penetration of its substrates to brain ECF and 
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transports these agents across the BBB into the systemic circulation. Similar to P-gp 
function on the BCSFB, BCRP was shown to transport its substrates into the CSF. In 
Bcrp1-/- mice, BCRP substrates showed lower CSF accumulation compared to wild-type 
mice (Shen et al., 2009; Zhuang et al., 2006). 
 
BCRP and P-gp show a considerable overlap in their substrate specificity. Recent 
reports suggested that BCRP and P-gp cooperate to limit CNS penetration of their dual 
substrates (Agarwal et al., 2010; de Vries et al., 2007; Shen et al., 2009). Several tyrosine 
kinase inhibitors were shown to be dual substrates for P-gp and BCRP. For example, in 
Bcrp1-/- mice or Mdr1a/b -/- mice, little to no difference was observed in brain penetration 
of several tyrosine kinases compared to wild-type mice. However, in Mdr1a/b-/-/Bcrp1-/- 
mice that lack both transporters, brain penetration of these agents are significantly 
elevated (Agarwal et al., 2011c; Chen et al., 2009; Polli et al., 2008). In some cases, drug 
levels in the brain are even higher than that in the systemic circulation which suggests a 
potential role of influx mechanisms responsible for the blood to brain transport of these 
molecules across the BBB (Agarwal et al., 2010; Kodaira et al., 2010; Kusuhara and 
Sugiyama, 2005). 
 
 
1.2.1.4. Pharmacological inhibition of efflux transporters 
 
Given the important effect of P-gp and BCRP on CNS anti-cancer drug 
disposition, several modulators of these transporters were developed in attempts to 
increase the delivery of anti-cancer drugs to therapeutically resistant tumors located 
behind the BBB. First generation inhibitors of P-gp were drugs known to be P-gp 
substrates such as verapamil and cyclosporin A. The use of these agents in combination 
with anti-cancer agents was associated with significant drug-related side effects in 
patients (Sikic et al., 1997). The increased toxicity can be explained by first, the lack of 
specificity and poor binding affinity of these agents to P-gp. Thus, transport inhibition 
can only be achieved at high exposures that can lead to toxicity. Second, verapamil and 
cyclosporin A are inhibitors of cytochrome P450 enzymes, which are commonly 
responsible for the metabolism of anti-cancer agents. Thus, combining non-specific P-gp 
modulator with anti-cancer agents resulted in lower systemic clearance and consequently 
increased toxicity of anti-cancer agents. 
 
Second generation modulators, such as the cyclosporin A analog, PSC833, are 
more specific and potent P-gp inhibitors. However, PSC833 also inhibited CYP3A 
enzymes. Therefore, third-generation inhibitors, such as elacridar (GF120918), and 
tariquidar (XR9576) (Hyafil et al., 1993; Roe et al., 1999), were developed to mainly 
modulate the transport function with little impact on liver metabolizing enzymes, which 
is reflected via better safety profiles in patients (Hyafil et al., 1993; Kruijtzer et al., 2002). 
Tariquidar is considered a specific P-gp inhibitor (Roe et al., 1999) while elacridar also 
inhibits human BCRP and mouse Bcrp1 (Hyafil et al., 1993; Maliepaard et al., 2001). To 
our knowledge, the efficacy of second or third generation transporter modulators in 
combination with molecularly targeted agents has not been assessed in patients with high-
grade glioma.  
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1.2.2. Solute carrier transporters 
 
 
1.2.2.1. Organic anion transporter-3 (OAT3) 
 
Oat3 is predominantly expressed on the basolateral side of mouse brain 
endothelial cells (Figure 1-3) (Ohtsuki et al., 2004). In rat brain, Oat3 is predominantly 
expressed on the basolateral side of the capillary endothelial cells with less expression on 
the luminal side (Kikuchi et al., 2003). This unique expression pattern enables Oat3 to 
mediate the transport of its substrates into or out of the brain. Reports studying CNS 
disposition of the typical Oat3 substrate p-aminohippurate (PAH) in rats showed both 
efflux and uptake processes of PAH to occur. However, the magnitude of PAH efflux 
was found to be 4 times higher than its uptake (Kusuhara et al., 1999; Kusuhara and 
Sugiyama, 2005). This suggests that Oat3 will have a net effect of extruding its substrates 
from the brain (Kusuhara and Sugiyama, 2005). 
 
On the choroid plexus, Oat3 is expressed on the basolateral border of the 
ependymal cells (Figure 1-4). Oat3 seems to mediate the transport of its substrates in an 
opposite direction to that of P-gp and BCRP (i.e., from the CSF to the blood) (Kikuchi et 
al., 2003; Sykes et al., 2004). 
 
Oat3 has been shown to transport several drugs with antitumor activity such as 
6-mercaptopurine and 6-thioguanine (Mori et al., 2004). However, further studies are 
warranted to assess the contribution of Oat3 to the disposition of anti-cancer agents used 
to treat glioma. 
 
 
1.2.2.2. Organic cation transporter-2 (OCT2) 
 
OCT2 is primarily expressed at the basolateral membrane of renal proximal 
tubules (Karbach et al., 2000; Motohashi et al., 2002) but it has also been detected in 
human neurons (Slitt et al., 2002). OCT2 is expressed on the apical side of human brain 
endothelial cells similar to the rodent orthologues, Oct1 and Oct2 (Figure 1-3) (Lin et al., 
2010). Typical OCT2 substrates are organic cations or weak bases (Nies et al., 2011). 
However, uncharged compounds such as cimetidine and non-ionizable compounds such 
as corticosteroids were shown to interact with OCT2 in a pH-dependent manner (Barendt 
and Wright, 2002). Further, OCT2 was shown to interact with organic anions such as 
probenecid (Hsyu et al., 1988).This substrate poly-specificity can be attributed to the 
existence of distinct hydrophobic and cationic sides on OCT2 (Rennick, 1981). 
 
On the BBB, OCT2 mediates the facilitated diffusion of several endogenous 
substrates and drugs. For example, the administration of the OCT2 inhibitor, amantadine, 
reduced the uptake of the OCT2 substrate, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
in brain ECF (Lin et al., 2010). On the BCSFB level, the role of OCT2 is not clear yet. 
OCT2 mRNA expression could not be detected on the rat choroid plexus epithelium 
which suggests minimal, if any, contribution of OCT2 to drug disposition across the 
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BCSFB (Choudhuri et al., 2003). Further studies are needed to understand the role of 
OCT2 in CNS disposition of several anti-cancer agents. The availability of Oct2-/- murine 
models will allow better understanding of the role of this transporter in carrier-mediated 
transport of several anti-cancer agents (Jonker et al., 2003). 
 
 
1.2.2.3. Organic anion transporter polypeptide 1A2 (OATP1A2) 
 
OATP1A2 is a member of the SLCO family of influx transporters that regulates 
the cellular level of several endogenous and exogenous compounds. OATP1A2 is 
expressed on the apical membrane of the brain endothelial cells. The expression of 
human OATP1A2 on the choroid plexus cells remains to be clarified. In rodents, two 
orthologues correspond to the human OATP1A2, Oatp1 and Oatp2. Oatp2 is highly 
expressed at both apical and basolateral membranes of the rat brain endothelial cells 
(Figure 1-3) while its localization in the choroid plexus is restricted to the basolateral 
membrane (Figure 1-4) (Angeletti et al., 1997; Gao et al., 1999). Oatp1 is not expressed 
at the BBB but its expression has been detected at the apical membrane of the choroid 
plexus (Figure 1-4) (Angeletti et al., 1997; Gao et al., 1999). 
 
Given the high expression levels of OATP1A2 in brain tissue and its broad 
spectrum of substrates, it is likely that this transporter play an important role in drug CNS 
disposition (Urquhart and Kim, 2009). For example, OATP1A2 was shown to play an 
important role in the transport of its substrates of opioid peptides across the BBB (Gao et 
al., 2000). Further, brain accumulation of several OATP1A2 substrates was reduced in 
mouse model lacking Oatp2 (Ose et al., 2010). Interestingly, several OATP1A2 
substrates, such as levofloxacin and methotrexate, are associated with severe CNS 
toxicity and thus OATP1A2-mediated transport may partially explain the CNS associated 
side effects with these agents (Maeda et al., 2007). In vitro, OATP1A2 has been shown to 
increase imatinib intracellular accumulation (Hu et al., 2008). Further investigation is 
warranted to elucidate the role of this transporter in disposition of other tyrosine kinase 
inhibitors. 
 
 
1.3. ANTI-CANCER DRUG PENETRATION IN HIGH-GRADE GLIOMAS 
 
 
1.3.1. The blood-tumor barrier in malignant glioma 
 
In contrast to the tightly regulated BBB in the normal brain, the BBB in high-
grade gliomas is structurally and functionally abnormal (Blakeley et al., 2009; Gerstner 
and Fine, 2007; Miyagami and Katayama, 2005). Abnormal features develop in response 
to the imbalance between the high demand of oxygen and nutrients by the rapidly 
proliferating tumor cells and the poor supply capacity of the existing blood vessels. Such 
imbalance, coupled with poor tumor lymphatic drainage, leads to a harsh tumor 
microenvironment characterized by hypoxia, decreased nutrients, and accumulation of 
metabolic wastes (Bergers and Benjamin, 2003; Fukumura and Jain, 2007; Jain, 2005; 
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Padera et al., 2002). Tumor cells overcome these unfavorable conditions by upregulating 
several proangiogenic factors such as VEGF (Ferrara, 2004), PDGF (Battegay et al., 
1994), and basic fibroblast growth factor (bFGF) (Friesel and Maciag, 1995). All these 
factors induce endothelial cell survival, proliferation, and migration by direct interaction 
with their receptors expressed on endothelial cells (Ucuzian et al., 2010). Upregulation of 
these proangiogenic factors initiates the development of neovasculature through the 
process of angiogenesis (Bergers and Benjamin, 2003; Jain et al., 2007). 
 
The newly developed tumor vessels represent a major determinant of glioma 
microenvironment and the principle means for anti-cancer drug delivery to the tumor. 
Therefore, the structural and functional properties of these vessels will significantly 
influence the concentration and distribution of anti-cancer agents throughout the tumor 
(Blakeley et al., 2009; Jain, 2005). 
 
While normal vessels consist of an organized network of venules, capillaries, and 
arterioles, tumor vessels are characterized by their heterogeneous distribution. Electron 
microscopic analysis of tumor endothelial cells in malignant gliomas indicated that they 
are composed of immature capillaries (Miyagami and Katayama, 2005). Structurally, 
these vessels are tortuous and dilated with abnormal basement membranes (Brown and 
Wilson, 2004; Carmeliet and Jain, 2000). Furthermore, tumor vessels lack direct physical 
contact with pericytes, which in normal vasculature are known to stabilize the endothelial 
cells and regulate their homeostasis and maturation (Figure 1-3) (Eberhard et al., 2000; 
Gerhardt and Betsholtz, 2003). Moreover, tumor vessels experience continuous 
compression from the rapidly dividing tumor cells (Padera et al., 2004). 
 
These structural defects render tumor vessels leaky with higher permeability when 
compared to normal vessels (Dvorak et al., 1995; Dvorak et al., 1999). The leakiness of 
tumor vessels will lead to extravasation of plasma components such as fibrin and albumin 
to brain ECF leading to increased interstitial fluid pressure, which is exacerbated by 
inefficient tumoral lymphatic drainage (Fukumura and Jain, 2007; Padera et al., 2002). 
The high interstitial fluid pressure results in tumor associated edema, which is a universal 
observation in gliomas and responsible for many of the disease associated symptoms 
(Fukumura and Jain, 2007; Papadopoulos et al., 2004). 
 
Because of the aforementioned hyperpermeablity, it is expected that anti-cancer 
drugs can accumulate more easily in tumor ECF. This may explain the high anti-cancer 
drug penetration reported in several preclinical and clinical trials of high-grade gliomas 
where drug accumulation in tumors was generally close, or sometimes higher, to plasma 
concentrations indicating a breached BBB. For example, Hofer et al reported high 
gefitinib concentrations (>10-fold of the plasma concentrations) in adult GBM patients 
(Hofer and Frei, 2007; Hofer et al., 2006). Several clinical and preclinical studies also 
reported similar results for other drugs such as methotrexate (Blakeley et al., 2009), 
temozolomide (Zhou and Gallo, 2009), topotecan (Carcaboso et al., 2010), and 
vincristine (Wang et al., 2010). 
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On the other hand, other studies considered poor CNS penetration of several 
chemotherapeutics to be a significant factor in the failure of these regimens in treatment 
of malignant glioma (Doolittle et al., 2007; Lassman et al., 2005; Motl et al., 2006b; 
Muldoon et al., 2007), suggesting that drug tumoral penetration is not solely dependent 
on the hyperpermeability of the endothelial cells within the tumor microenvironment but 
also depends on the physicochemical properties of the drug. 
 
It is also important to note that only the vessels at the tumor core are considered 
hyper-permeable and leaky. The leading tumor edge that invades through brain 
parenchyma is thought to make use of the existing normal brain vasculature with a 
relatively intact BBB. These intact endothelial cells will limit drug accumulation at the 
tumor edge (Fine et al., 2006; Gilbertson and Rich, 2007; Pitz et al., 2011). Thus, anti-
cancer drug concentrations are expected to be higher at the core than at the invasive 
proliferative edge of the tumor (Gerstner and Fine, 2007; Pitz et al., 2011). This concept 
was supported by a clinical trial assessing paclitaxel concentrations at the tumor core, 
tumor periphery, and at the tumor-normal brain interface in high-grade glioma patients. 
Highest levels of paclitaxel were found in the tumor core, followed by the tumor 
periphery, with lowest paclitaxel concentrations found in the normal surrounding brain 
tissue (Fine et al., 2006; Gerstner and Fine, 2007). Improving the delivery of anti-cancer 
drugs to the clinically challenging infiltrative tumor cells may improve treatment 
outcome of high-grade glioma as these invasive cells represent a clinical challenge and 
are considered an important determinant for tumor recurrence (Giese et al., 2003). 
 
 
1.3.2. The glioma cell barrier 
 
High-grade glioma is composed of three distinct, yet interrelated, compartments. 
First, a vascular compartment formed of both existing blood vessels from normal brain 
tissue and newly developed tumor vasculature. The second is the ECF compartment, and 
the third is the intracellular compartment where most drugs currently used in treatment of 
high grade gliomas exert their anti-tumor effect (Baselga, 2006; Hammarlund-Udenaes, 
2010; Hammarlund-Udenaes et al., 2008; Reichel, 2009). Though this three-compartment 
concept may not reflect the pathological complexity of the tumor, it provides a useful 
platform to understand drug trafficking mechanisms within different tumor 
compartments. 
 
Anti-cancer drug disposition within these three compartments is determined by 
intricate microenvironmental properties of each compartment. Drug diffusion from the 
vascular to the ECF compartments is controlled by the leakiness of the vessels as well as 
the high interstitial fluid pressure. On one hand, anti-cancer agents may diffuse from the 
leaky tumor vessels and accumulate in tumor ECF compartment (Blakeley et al., 2009; 
Carcaboso et al., 2010; Hofer and Frei, 2007; Hofer et al., 2006; Zhou and Gallo, 2009). 
On the other hand, the lack of pressure difference between the vascular and interstitial 
fluid compartments, as a result of the high interstitial fluid pressure, may lead to a 
stagnant blood flow which will limit drug accumulation in tumor ECF (Fukumura and 
Jain, 2007). 
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Several studies assessing anti-cancer drug penetration at the tumor core of high-
grade glioma ECF show high tumor penetration ratio relative to plasma concentrations 
(Blakeley et al., 2009; Carcaboso et al., 2010). This suggests that anti-cancer agents are 
capable of reaching the tumor ECF. Determining whether the anti-cancer drug 
concentration achieved within the tumor is therapeutically effective requires determining 
the unbound drug concentrations at the active site. Most anti-cancer agents currently used 
for treatment of high-grade glioma exert their anti-tumor effect by interacting with 
intracellular targets. Even drugs that target receptor tyrosine kinases expressed on tumor 
cell membranes often interact with cytoplasmic domains of their targets and thus require 
intracellular accumulation of these agents (reviewed in Baselga, 2006). 
 
Efflux transporters expressed on glioma cell membranes restrict intracellular 
accumulation of anti-cancer drugs and therefore provides an additional barrier (Agarwal 
et al., 2011b; Lee et al., 2001). Several reports showed the expression of P-gp 
(Calatozzolo et al., 2005; Decleves et al., 2002; Demeule et al., 2001; Fattori et al., 2007; 
Nabors et al., 1991), BCRP (Carcaboso et al., 2010; Decleves et al., 2006), as well as 
MRPs 1 and 4 (Bronger et al., 2005; Calatozzolo et al., 2005; Decleves et al., 2002; 
Mohri et al., 2000) in cases of malignant glioma. 
 
Due to the effect of efflux transporters on glioma cell membrane, anti-cancer 
drugs may accumulate in the ECF compartment while only a fraction of the drug can 
accumulate inside the tumor cell (Carcaboso et al., 2010). Furthermore, only a fraction of 
the drug that reaches the intracellular compartment will be free to interact with its target 
while the rest remains nonspecifically bound to intracellular lipids and proteins 
(Hammarlund-Udenaes et al., 2008; Reichel, 2009). This will further reduce the amount 
of drug available to exert anti-tumor effect (Hammarlund-Udenaes, 2010; Hammarlund-
Udenaes et al., 2008; Maurer et al., 2005; Reichel, 2009). Unfortunately, very little 
information is known about intracellular drug accumulation due to the difficulty of 
sampling the intracellular compartment in vivo. Thus, determining whether 
therapeutically effective concentrations can be achieved at the target site cannot be 
directly assessed in vivo using currently available methodologies (Hammarlund-Udenaes 
et al., 2008; Reichel, 2009). 
 
Most of the studies assessing anti-cancer tumoral penetration rely on brain 
homogenization techniques. Several of these studies reported high tumor penetration 
profiles of anti-cancer drugs relative to plasma concentrations (e.g., gefitinib tumor 
concentrations reported to be more than 10-fold higher than that of the plasma 
concentrations) (Hofer and Frei, 2007). The techniques applied in these studies do not 
discern between any of the three tumor compartments. They also do not account for 
binding of the drug to proteins either in plasma or in tumor tissue. Therefore, no 
conclusions can be made regarding whether the achieved concentrations of the unbound 
drug at the target site are effective or not. 
 
A study conducted by our group assessing intracellular topotecan distribution by 
analyzing both total and ECF concentrations in an orthotopic xenograft mouse model of 
glioma showed an inverse correlation between ECF concentrations and intracellular 
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distribution (i.e., higher ECF concentrations correlate with lower intracellular 
distribution). Inhibiting efflux transporters, specifically P-gp and BCRP, at the tumor cell 
membrane decreased topotecan ECF concentrations and increased its intracellular 
distribution, indicating a critical role of efflux transporters in limiting anti-cancer drug 
access to the intracellular compartment (Carcaboso et al., 2010). 
 
The complexity of assessing anti-cancer drug penetration in different tumoral 
compartments underscores the importance of understanding the different methods used to 
sample each compartment as well as the need for clinically relevant animal models that 
recapitulate features of the human disease. In the next two sections, animal models of 
high grade glioma currently available to study anti-cancer drug penetration and the 
approaches used to evaluate drug penetration within the tumor will be discussed. 
 
 
1.4. MURINE MODELS OF MALIGNANT GLIOMA 
 
The need for clinically relevant murine models of high-grade glioma is 
compelling. Such models will allow researchers to translate their findings from 
preclinical experiments to the bedside. The ideal murine model for studying anti-cancer 
drug accumulation in glial tumors should accurately recapitulate the histological features 
of high-grade glioma including hypoxia, intense vascular proliferation, and the invasive 
growth pattern of these tumors. This model should also reflect the interaction between the 
tumor and host stroma. Tumors in such an ideal model should have high penetrance and a 
reasonable latency that allows growth of tumors within adequate period that reflects, even 
partially, the human disease while still providing a window for testing of anti-cancer 
agents before the animals become moribund. Finally, such a model should mimic the 
genetic profile of high-grade glioma observed in patients. 
 
Despite the availability of several murine models of malignant glioma, an ideal 
model that recapitulates all aspects of the disease does not exist. Every model provides a 
set of advantages and disadvantages to the research question. Depending on the purpose 
of the experiment, investigators should weigh the pros and cons of the models available 
and decide which model provides an adequate recapitulation of important effectors 
regarding their experiment. In this section, the pros and cons of some of the available 
models will be discussed with emphasis on their relevance to glioma histology, tumor 
microenvironment, genetic representation, and their suitability for drug penetration 
studies. 
 
 
1.4.1. Subcutaneous xenograft models 
 
Due to their relatively short latency, ease of establishment, predictable growth 
pattern, and the simplicity of monitoring tumor growth without the need for complex 
imaging techniques, subcutaneously implanted xenograft models are widely used for 
monitoring tumor response to chemotherapeutic regimens. Tumors implanted in these 
models commonly display features of hypoxia (Gillespie et al., 2007) and the 
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development of neovasculature (Kim et al., 1993; Saleh et al., 1996). However, 
subcutaneous tumors fail to provide adequate resemblance to the microenvironment or 
growth pattern of intracranial glioma tumors in humans. For example, subcutaneously 
implanted models do not acquire the invasive growth characteristics of high-grade 
gliomas and grow mainly as a “bag” of tumor cells, bearing no resemblance to glial 
tumors (Antunes et al., 2000). 
 
Further, the gene expression profiles of glioma cell lines implanted 
subcutaneously in nude mice was significantly different from intracranial tumors 
established from the same cell lines (Camphausen et al., 2005a; b). This indicates that 
subcutaneous growth of subcutaneous tumors provides different and probably irrelevant 
in vivo growth conditions (Camphausen et al., 2005a; b). 
 
The use of these models to determine drug tumoral penetration is inadequate as 
these models neither recapitulate the degree of high-grade glioma microvascular 
proliferation nor the different CNS barriers against drug penetration (de Vries et al., 
2009). This is supported by reports showing different penetration profiles of anti-cancer 
drugs in subcutaneous tumors when compared to their orthotopic counterparts (Ma et al., 
2003). Consequently, anti-cancer drug penetration studies conducted using subcutaneous 
xenograft models are not indicative of the intracranial tumor situation and thus these 
models should not be used to study CNS drug penetration. 
 
 
1.4.2. Orthotopic xenograft models 
 
The relative ease of engraftment, rapid tumor growth, and short latency from 
tumor inoculation until morbidity have made orthotopic xenograft models an essential 
tool for in vivo efficacy studies of anti-cancer drugs in the past decade. These models are 
considered more appropriate than subcutaneous xenograft models in predicting drug 
efficacy and CNS drug penetration. However, concerns have been expressed regarding 
the clinical relevance of the tumor microenvironment in these models and whether they 
represent accurate models to study anti-cancer drug penetration to glial tumors. 
 
Although some orthotopic xenograft models provide adequate recapitulation of 
the histological and invasive properties of malignant gliomas (e.g., U251) (Houchens et 
al., 1983; Radaelli et al., 2009), many commonly used models fail to recapitulate any of 
these properties (Becher and Holland, 2006; Jacobs et al., 2011). For example, upon 
intracranial inoculation of U87–MG cells in immune compromised mice, huge 
circumscribed tumors with clear tumor edge separating the tumor tissue from the 
surrounding normal brain are formed (Carcaboso et al., 2010; de Vries et al., 2009; 
Radaelli et al., 2009). As mentioned earlier, this growth pattern is vastly different from 
that of infiltrative tumors observed in patients (Giese et al., 2003). Unfortunately, 
U87-MG cell line has been one of the most frequently used cell lines for xenograft 
studies. This cell line has significantly contributed, perhaps in a biased way, to our 
understanding of high-grade gliomas. 
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Another pitfall of xenograft models in general is their reliance on in vitro 
culturing of tumor cells. Cells are cultured on plastic plates or flasks may acquire or lose 
novel genetic properties (Camphausen et al., 2005a; b; Kucherlapati, 2012). For example, 
GBM cell lines cultured in vitro cannot preserve EGFR focal amplification, a common 
genetic alteration in ~50% of adult patients with GBM (Pandita et al., 2004). Attempts to 
preserve the genetic properties of the original tumor included direct implantation of 
tumors from patients in immune-compromised mice (Pandita et al., 2004). Other trials 
focused on in vitro culturing of primary tumor cells under serum-free neurobasal media 
supplemented with different concentrations of growth factors such as EGF and bFGF 
instead of serum-based culture conditions (Lee et al., 2006; Schulte et al., 2012). Further 
studies are required to demonstrate the benefit of these approaches on recapitulating the 
features of the original tumor (Schulte et al., 2012). 
 
Importantly, a tumor implanted in an immune compromised host lacks the 
contribution of the host-tumor interaction, which may impact the tumor propensity to 
invade, metastasize, and develop new blood vessels (Becher and Holland, 2006). This 
may explain the inability of several orthotopic glioma models to recapitulate many of the 
histological features of HGGs including the invasiveness and the intense microvascular 
proliferation. 
 
Orthotopic xenograft models are used, almost exclusively, for drug penetration 
studies in high-grade gliomas as they provide some depiction of the different CNS 
barriers (Carcaboso et al., 2010; Ma et al., 2003). Some inherent limitations of these 
models are unlikely to be avoided such as the genetic properties acquired on culture and 
the inability to recapitulate the host-tumor interaction. However, adequate orthotopic 
models for drug penetration studies should recapitulate tumor invasiveness and 
microvascular proliferation observed in human tumors. In general, the data obtained 
using these models should be interpreted in light of the limitations discussed earlier. 
 
 
1.4.3. Genetically engineered mouse models 
 
Given all the aforementioned shortcomings of glioma xenograft models together 
with the advancements in gene targeting technologies, more focus has been directed to 
develop genetically engineered mouse models (GEMMs) that can represent the genetic 
profile and histological features of high-grade glioma including the invasive growth 
pattern of these tumors. In general, these models reproduce the microenvironment of 
high-grade glial tumors better than xenograft models (Becher and Holland, 2006; Chow 
and Baker, 2012; Kucherlapati, 2012). 
 
GEMMs can be categorized into germ-line and somatic GEMMs. In germ-line 
GEMMs, genetic alterations are introduced in the embryonic stage and is maintained 
through breeding (Aguzzi et al., 1994; Heyer et al., 2010). Germ-line GEMMs are 
beyond the scope of our discussion. The reader is directed to several excellent research 
articles and reviews where germ-line GEMMs have been discussed in more detail (de 
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Vries et al., 2009; Ding et al., 2001; Reilly et al., 2000; Wang et al., 2009; Xiao et al., 
2002; Zhu et al., 2005). 
 
Somatic GEMMs harbor genetic alterations in some of its somatic cells but not in 
the germ line cells. Of these, conditional GEMMs enable the induction of the genetic 
event in a temporally and spatially controlled manner (i.e., the genetic alteration can be 
induced at a certain time during the mouse development and in a certain subset of cells 
(Gossen and Bujard, 1992; Heyer et al., 2010). In this section, we will highlight some of 
the recently reported somatic GEMMs that may provide reasonable tools for studying 
anti-cancer drug penetration in high-grade gliomas. 
 
Marumoto and colleagues reported a novel GEMM that recapitulates most 
features of high-grade gliomas (Marumoto et al., 2009). Tumors develop upon 
stereotactic injection of lentiviral vectors expressing H-RasV12 and AKT oncogenes in 
immune compromised mice with GFAP-Cre/p53+/- background that restricts the 
expression of H-RasV12 and AKT oncogenes to GFAP (glial fibrillary acidic protein) 
expressing cells, i.e. astrocytes and neural progenitor cells. Tumors can be established in 
different brain locations with variable degree of penetrance (hippocampus 100%, 
subventricular zone 75%, and the cortex 7%) (Marumoto et al., 2009). 
 
The genetic drivers of this model are different from that observed in patients. 
While RTK/PI3K pathway is frequently deregulated in gliomas (Guha et al., 1997; 
Pollack et al.), Ras mutation and AKT amplification are relatively rare events in high-
grade gliomas (~2% for each) (TCGA, 2008). Other concerns noted about the viral 
delivery approach include unpredictable delivery and efficiency which may result in 
different cell groups transduced with either one of these oncogenes (Ras and AKT) or 
both leading to multiple tumor types in the same mouse (de Vries et al., 2009; Heyer et 
al., 2010). Finally, the contribution of the host immune response to tumor growth is 
lacking in this model as tumors are generated in immune compromised mice (Marumoto 
et al., 2009). 
 
Tumors of this model showed many of the histological features of high-grade 
gliomas including high cellularity, necrosis, invasiveness through brain parenchyma, and 
a high degree of vascular proliferation. Reasonable latency (~ 3 months) was observed 
for the development of these tumors. These properties render this model a reasonable 
model to study anti-cancer drug penetration in glioma (Marumoto et al., 2009). 
 
Another recently reported model involves intracranial injection of GFAP-Cre or 
CMV-Cre in compound LoxP-conditional mice with p53 or pten deletions (de Vries et 
al., 2010). Viral transduction of Cre leads to K-RasV12 expression and deletion of the 
tumor suppressor gene Ink4a/Arf, resulting in high-grade astrocytoma with 100% 
penetrance. These tumors demonstrate most of the histological features of high-grade 
glioma tumors with increased mitosis, nuclear atypia, giant cell formation, and 
pseudopalisading necrosis. Tumor vessels of this model express BCRP, a feature 
observed in vessels from human glioblastoma (Zhang et al., 2003). Since these tumors are 
luciferase-labeled, their growth can be easily monitored using bioluminescence. 
 
 
27 
As noted in the previous model, Ras mutations are rare genetic events in glioma 
and thus the genetics of this model might not be representative of the human disease. 
However, this model presents a useful tool which combines the relative ease of induction, 
simple monitoring of tumor growth, and retaining important markers of tumor 
vasculature (de Vries et al., 2010). Unfortunately, this model did not show glioma-like 
angiogenic features and thus lacks an important determinant of tumoral drug penetration 
in high-grade glioma. 
 
Another tumor model to induce conditional loss of function is the inducible 
CreERTM-loxP system, which allows temporal and spatial control of somatic deletion of 
tumor suppressor genes (Gossen and Bujard, 1992; Jonkers and Berns, 2002). Cre 
recombinase is expressed under the control of the promoter of a site-specific marker (e.g., 
GFAP in case of astrocytes and neural precursors). Administering the inducer (e.g., 
tamoxifen) will result in nuclear translocation of the Cre recombinase, which induces 
somatic deletion of “floxed” tumor suppressor genes (Metzger and Feil, 1999; Pluck, 
1996). 
 
Few glioma models using this system have been reported. For example, Liaguno 
and colleagues showed that deletion of tumor suppressor genes Nf1, p53, and/or Pten in 
Nestin-expressing cells lead to development of high-grade gliomas (Alcantara Llaguno et 
al., 2009). Tumors of this model showed all of the typical histological features of high-
grade gliomas within ~4 months of induction with 100% penetrance. Finally, Chow et al 
used CreERTM-loxP system to show that deletion of p53, Pten, and Rb results in initiation 
of high-grade astrocytoma with high penetrance (~85%) (Chow and Baker, 2012; Chow 
et al., 2011). 
 
Both CreERTM-loxP dependent models discussed above bestow many of the 
genetic and histological features of malignant glioma. Another point to note is the 
heterogeneity associated with the tumor location, histology, and the secondary 
spontaneous mutations associated with these models (Alcantara Llaguno et al., 2009; 
Chow et al., 2011). While this feature provides better recapitulation of the heterogeneous 
nature of malignant glioma, it adds more complexity to conducting preclinical 
experiments and interpreting the results. Other pitfalls of these models are the relatively 
long latency of tumor growth (~4-6 months) and the relative difficulty of monitoring in 
situ tumor growth. However, with better experimental design in monitoring tumor growth 
and location, the use of novel imaging modalities such as MRI, and careful scheduling of 
experiments before animals succumb to disease, these models can provide an attractive 
tool to study anti-cancer drug penetration to high-grade glioma. 
 
 
1.5. APPROACHES TO EVALUATE ANTI-CANCER DRUG PENETRATION 
IN BRAIN TUMORS 
 
The extent of drug penetration within brain tumors can be calculated as the ratio 
of unbound drug concentrations in the tumor relative to unbound concentrations in the 
plasma at steady state, or by the ratio of unbound area under the curve (AUC) in tumor 
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relative to unbound plasma AUC. Different sampling strategies and pharmacokinetic 
approaches have been used to determine tumoral drug penetration. These methods differ 
in the number of samples that can be obtained, their ability to provide compartment-
specific information about drug penetration, and their ability to account for drug protein 
binding. In this section, the pros and cons of these methods will be briefly discussed. 
 
 
1.5.1. Whole tissue homogenization 
 
Due to the ease of sample collection and processing, most preclinical and clinical 
studies have relied on homogenizing whole brain or tumor samples to study anti-cancer 
drug concentration expressed as the amount of drug per gram tissue (e.g., ng/gm tissue) 
(Hofer and Frei, 2007; Hofer et al., 2006; Lassman et al., 2005; Zhou and Gallo, 2009). 
In preclinical studies, this method involves sacrificing 3-6 animals per time point and 
collecting blood and tissue at each time point. Therefore, large numbers of animals are 
required, typically around 25-40 animals per study (Zhou and Gallo, 2009). In clinical 
studies, tumor tissue can be collected only during surgical removal of the tumor and thus 
only one time point can be studied in each patient. 
 
This method does not discern between different tumor compartments (e.g., 
vascular, ECF, and intracellular), and consequently fails to provide information about 
anti-cancer drug concentration within any specific compartment. This method considers 
the tumor one homogenous entity and thus provides the total drug concentration in all 
tumor compartments. 
 
Another limitation to tumor homogenization is that it does not account for drug 
binding to the tumor tissue. Only unbound drug can pass through the barriers, enter tumor 
cells, bind to its target and exert the anti-tumor effect (de Lange and Danhof, 2002; Smith 
et al., 2010). High total drug concentration in the tumor (Atumor) can be misleading, as it 
does not necessarily reflect high pharmacologically available concentrations at the active 
site. In other words, Atumor may reflect drug in the vascular compartment, ECF 
compartment, or even drug bound to nonspecific, off target intracellular proteins. It is 
also important to mention that binding of the drug in brain or tumor is different from that 
in plasma due to different protein and lipid contents between plasma and brain 
(Richmond, 1985). 
 
 
1.5.2. CSF Sampling 
 
CSF sampling is an alternative method to study CNS and tumor drug disposition 
(Shen et al., 2004). This method provides information on the unbound drug 
concentrations (Lin, 2008). As discussed earlier, CSF is separated from the blood via the 
BCSFB, which is mainly dependent on efflux transporters expressed at either apical or 
abluminal sides of the choroid plexus (Motl et al., 2006a). CSF sampling is commonly 
obtained through a procedure known as lumbar puncture which usually provides a single 
CSF sample (Hill et al., 1999). However, for serial sampling a cannula should be inserted 
 
 
29 
in the cisterna magna (Bruce and Oldfield, 1988; Schumann and Crisman, 1985). Given 
the ease of obtaining serial samples from this method, several preclinical and clinical 
studies relied on CSF sampling as a surrogate for brain or tumor concentrations (Blaney 
et al., 1998; Broniscer et al., 2007b; Vanbree et al., 1989; Vistelle et al., 1994). 
 
However, evidence from several reports suggests that CSF concentrations are 
poor surrogates of brain ECF concentrations (de Lange and Danhof, 2002; Lin, 2008). 
For example, several P-gp substrates exhibit different penetration profiles in brain ECF 
compared to CSF (Shen et al., 2009). This can be explained by P-gp localization at the 
BBB and the BCSFB, which allows P-gp to transport its substrates from brain ECF to 
blood at the BBB and into the ventricular CSF at the BCSFB. Similar reports showing 
different CSF and ECF penetration of several other drugs are available (e.g. morphine, 
nelfinavir, and antipyrine) (Kaddoumi et al., 2007; Mayer et al., 1959; Stain-Texier et al., 
1999). Further, the increased BBB permeability observed at the core of high-grade 
glioma tumors is likely to cause different penetration profiles in tumor ECF than in CSF, 
which means that CSF concentrations cannot be used as a surrogate to estimate tumor 
ECF concentrations (Stain-Texier et al., 1999). 
 
 
1.5.3. Cerebral microdialysis 
 
Cerebral microdialysis is a sampling technique that involves the insertion of a 
semi-permeable probe into the target tissue (e.g., brain or tumor). This probe is then 
perfused by a solution (i.e. perfusate) that mimics the composition of the target tissue 
(e.g., ECF or CSF). Molecules (e.g., anti-cancer drug) in the target tissue will diffuse 
through the semi-permeable membrane according to their concentration gradient. Finally, 
the collected sample (i.e. dialysate) is analyzed using analytical methods sensitive enough 
to detect the drug in the small sample volume collected. 
 
Microdialysis provides a useful tool to sample a distinct tissue compartment, the 
ECF or ventricular CSF. An important advantage of this technique is that only unbound 
drug can pass through the pores of the semi-permeable membrane given the low 
molecular weight cutoff of the probe (~ 5 kDa) (Tsai, 2003). Therefore, inserting a 
microdialysis probe in the tumor can allow investigators to determine the unbound 
(active) drug concentration in the ECF (Tsai, 2003). It also allows serial sampling from a 
single animal, thus reducing the number of animals required for preclinical studies (de 
Lange et al., 1997; Hammarlund-Udenaes et al., 1997). 
 
Microdialysis is used for ECF sampling for analysis of a single anti-cancer agent. 
However, the resistant nature of some CNS tumors renders combination regimens a 
plausible approach to overcome tumor resistance (Brown et al., 2008; Fan and Weiss, 
2010; Karpel-Massler et al., 2011; Krakstad and Chekenya, 2010; Prados et al., 2006). To 
our knowledge, no studies have been published that show the feasibility of simultaneous 
microdialysis sampling of multiple anti-cancer agents. Thus, a robust method to 
simultaneously sample multiple anti-cancer agents coupled with sensitive analytical 
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methods can prove useful in determining the penetration profile of anti-cancer agents 
administered in combination. 
 
Microdialysis has many advantages over other methods to assess CNS drug 
disposition, but it does have limitations. A limitation of microdialysis is the trauma 
associated with surgical insertion of the probe in the tissue. This raises some concerns to 
whether inserting the probe may damage the endothelial cells of the BBB and thus limit 
the suitability of microdialysis to study BBB-related questions. Several studies have 
evaluated the trauma associated with implanting a microdialysis probe. For example, 
cerebral blood flow was disturbed 2 hours after probe implantation in rat brains. After 24 
hours, cerebral blood flow is restored and no major disturbances could be detected 
(Benveniste et al., 1987). For cerebral tumors, implanting microdialysis probes showed 
no signs of inflammation for ~ 3 days. After 3 days of implantation, a mild tissue reaction 
manifested as gliosis was detected around the probe. This reaction was shown not to 
affect BBB transport (de Lange et al., 1994). Generally, histological evaluation 
performed in several microdialysis studies showed only mild tissue trauma, if any, after 
probe implantation, which is not likely to affect BBB integrity (Carcaboso et al., 2010; 
Elmeliegy et al., 2011a; Elmeliegy et al., 2011b). Finally, if probe implantation damages 
the BBB, one would speculate that substances that typically cannot penetrate to the brain 
would show higher brain accumulation after probe implantation. However, brain 
accumulation of integrity markers such as fluorescein dextran and 14C-alpha-amino-
isobutyric acid was not increased after probe implantation indicating that BBB integrity 
was preserved (Benveniste et al., 1984; de Lange et al., 1998). 
 
Several microdialysis studies have been conducted in orthotopic glioma 
xenografts (Ma et al., 2003; Ma et al., 2001). However, GEMMs have never been used in 
microdialysis studies. Several reasons may contribute to the difficulty of using GEMMs 
in microdialysis studies. One reason is the need for complex and costly imaging 
techniques to determine brain tumor location. Such expensive imaging modalities (e.g. 
MRI) are not necessarily available in all research institutes. 
 
Another reason is the technical challenge of implanting the microdialysis cannula 
and probe in the spontaneously developed tumor given the heterogeneity commonly 
associated with these models. Implanting microdialysis cannulas in orthotopic xenograft 
models is relatively easy and can be established by stereotactically injecting tumor cells 
followed by microdialysis cannula/probe using the intersection between the coronal and 
sagittal sutures, i.e. the bregma point, as a reference point (Carcaboso et al., 2010; Ma et 
al., 2003). However, the bregma point does not appear on images derived by MRI. The 
lack of common reference points between the MRI images and the mouse skull renders 
accurate determination of implantation coordinates in GEMMs rather challenging. New 
methodologies to guide microdialysis cannula implantation using a reference point visible 
on MRI may prove useful for CNS penetration studies in GEMMs. 
 
Another limitation that prevented the use of cerebral microdialysis in GEMMs is 
that, in many cases identification of the tumor can only be accomplished at a late stage at 
which surgical implantation of the cannula and performing the microdialysis experiment 
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is technically not feasible. These problems can be addressed using novel imaging 
techniques such as MRI to identify the tumor location prior to surgically implanting the 
cannula. 
 
During a microdialysis experiment, drug concentration in tissue ECF is more than 
in the perfusate and therefore true equilibrium conditions cannot be achieved. Thus, 
concentrations in the dialysate will be different from that in tissue ECF. Therefore, 
relating dialysate concentrations to tissue ECF concentrations, i.e. estimating the extent 
of drug recovery from tissue ECF through the probe, is an important step in the design of 
the microdialysis experiment. Several methods to calculate probe recovery have been 
reported (reviewed in de Lange et al., 1997). We will limit our discussion to two of the 
major recovery determination methods, namely retrodialysis and zero flow rate. 
 
 
1.5.3.1. Retrodialysis 
 
In this method, a known concentration of the drug is prepared in the perfusate and 
pumped through the probe. The basic assumption of the retrodialysis method is that the 
diffusion process across the microdialysis probe is quantitatively equal in both directions 
i.e. the percentage of the analyte lost from the perfusate to the medium is equal to the 
percentage recovered from the medium to the perfusate (Figure 1-5) (Wang et al., 
1993b). This method should be conducted when there is no drug present in the body, e.g. 
before administering the drug.  
 
 
1.5.3.2. Zero flow rate 
 
The extent of recovery is inversely proportional to the flow rate of the perfusate 
i.e. the lower the flow rate, the higher the probe recovery (Jacobson and Hamberger, 
1985; Johnson and Justice, 1983; Lindefors et al., 1989). The zero flow rate (ZFR) 
method is applied by collecting dialysates at several flow rates, measuring different 
dialysate concentrations, and plotting the concentrations against the flow rate. The basic 
hypothesis of this method is that extrapolation to a hypothetical flow rate of zero provides 
an estimate of the absolute drug concentration in tissue ECF (Jacobson et al., 1985). The 
ZFR requires drug concentration to remain relatively constant while collecting the 
dialysates at different flow rates (Jacobson et al., 1985). 
 
 
1.6. SUMMARY 
 
For the past three decades, little progress has been achieved in the treatment of 
malignant glioma in both adults and pediatric populations. The recent advances in tumor 
genotyping identified important genetic alterations in disease development and 
progression. However, several clinical trials showed that molecularly targeted agents that 
target these genetic alterations failed to provide significant therapeutic benefit for 
malignant glioma patients. Inadequate penetration of these agents to the tumor may 
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Figure 1-5. Diagrammatic illustration of the retrodialysis method 
 
Retrodialysis experiment (upper panel) is conducted by perfusing drug prepared 
in perfusate (Cin) through the probe. A fraction of the drug will be lost across the 
probe. Percent of drug lost through probe can be calculated as 
100	X	 ቀେ୧୬ିେ୭୳୲େ୧୬ ቁ.	The underlying assumption of this method is that the 
percentage of drug lost across the membrane is equal to that gained from the 
tissue ECF during the experiment (lower panel). 
 
Source: Reprinted by permission from Elsevier. de Lange et al. (2000) 
Methodological issues in microdialysis sampling for pharmacokinetic studies. 
Advanced Drug Delivery Reviews 45:125-148. 
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partially explain the failure encountered in the clinics. Delivery of these agents to the 
tumor can be influenced by several efflux and uptake transporters expressed at the BBB 
and the BCSFB. Through this project, we investigated the effect of major efflux and 
uptake transporters at the BBB and the BCSFB on the penetration of two tyrosine kinase 
inhibitors, erlotinib and crenolanib. We also studied erlotinib and crenolanib penetration 
in murine models of high-grade glioma using cerebral microdialysis. 
 
 
1.7. SPECIFIC AIMS 
 
The objective of specific aim 1 was to assess the role of efflux and uptake 
transporters in erlotinib CNS penetration and intracellular accumulation. 
 
The objective of specific aim 2 was to use MRI imaging to identify a reference 
point for implanting microdialysis cannula in spontaneously arising tumors in a GEMM 
for high-grade glioma. 
 
The objective of specific aim 3 was to demonstrate the feasibility of simultaneous 
sampling of multiple anti-cancer agents, erlotinib and crenolanib, via cerebral 
microdialysis.  
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CHAPTER 2.    ROLE OF ATP-BINDING CASSETTE AND SOLUTE CARRIER 
TRANSPORTERS IN ERLOTINIB CNS PENETRATION AND 
INTRACELLULAR ACCUMULATION* 
 
 
2.1. INTRODUCTION 
 
Erlotinib (TarcevaTM) is an orally administered epidermal growth factor receptor 
(EGFR) inhibitor approved for certain types of non-small cell lung cancer (NSCLC) and 
pancreatic cancer (Shepherd et al., 2005). In humans, erlotinib is extensively metabolized 
primarily by hepatic CYP3A4 and CYP3A5 with some metabolism by CYP1A2 and 
CYP2C8 (Ling et al., 2006). The metabolite, OSI-420, retains EGFR tyrosine kinase 
inhibitory activity as well as in vivo tumor growth inhibitory activity (Moyer et al., 
1997). 
 
Clinical trials have evaluated the safety and activity of erlotinib in patients with 
primary and secondary central nervous system (CNS) tumors with frequent EGFR 
alterations, such as high-grade glioma and brain metastases of NSCLC (Broniscer et al., 
2009; Sun et al., 2009). In most of these studies, erlotinib failed to show clinically 
significant activity (Broniscer et al., 2009; Shepherd et al., 2005; van den Bent et al., 
2009a). A potential explanation for this lack of efficacy is that the BBB prevents the 
accumulation of effective erlotinib concentrations in the tumor (Loscher and Potschka, 
2005; Shen et al., 2004). This is supported by evidence from clinical studies showing low 
erlotinib and OSI-420 accumulation in high-grade glioma (Lassman et al., 2005; Raizer et 
al., 2010a). 
 
One mechanism by which the BBB limits erlotinib CNS penetration is the 
expression of efflux proteins of the ATP-binding cassette (ABC) transporter family at the 
brain endothelial cells (Giacomini et al., 2010). ABC transporters likely to impede 
erlotinib CNS distribution include P-glycoprotein (P-gp/MDR1/ABCB1; Mdr1a/b in 
mice), breast cancer resistance protein (BCRP/ABCG2; Bcrp1/Abcg2 in mice), and the 
multidrug resistance-associated protein 4 (MRP4/ABCC4; Mrp4/Abcc4 in mice) 
(Kodaira et al., 2010; Leggas et al., 2004a). Expression of efflux transporters on tumor 
cell membranes would be an additional mechanism of drug resistance preventing the 
intracellular penetration of anti-cancer drugs (Carcaboso et al., 2010). 
 
In addition to ABC transporters, uptake transporters located at the BBB or at the 
blood-tumor barrier could also regulate drug delivery to the CNS and brain tumors (Ose 
et al., 2010). Several uptake transporters of the SLC22A family are localized at the BBB 
or at the blood cerebrospinal fluid barrier (BCSFB) where they affect the disposition of  
 
 
*Reprinted with permission. Elmeliegy MA et al. (2011) Role of ATP-binding cassette 
and solute carrier transporters in erlotinib CNS penetration and intracellular 
accumulation. Clin Cancer Res 17:89-99. 
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their substrates (Kikuchi et al., 2003; Kusuhara and Sugiyama, 2005; Lin et al., 2010; 
Nagata et al., 2002). 
 
The expression of some uptake transporters is detected in vessels of high-grade 
glioma where they may affect drug accumulation inside the tumor (Bronger et al., 2005). 
However, the affinity of these transporters towards many anti-cancer agents, including 
erlotinib, has not been studied. 
 
Erlotinib concentrations in the cerebrospinal fluid (CSF) of patients with brain 
tumors have been previously reported as 8% of the total plasma concentration (Broniscer 
et al., 2007b; Togashi et al.). However, several studies in animals have demonstrated 
differential (usually increased) drug distribution in the CSF as compared to the brain 
parenchyma extracellular fluid (ECF) (Kaddoumi et al., 2007; Shen et al., 2009; Stain-
Texier et al., 1999), emphasizing the limitations of using CSF sampling, or whole brain 
homogenates, to examine CNS drug penetration. 
 
In the present study, we used cerebral microdialysis sampling to assess the role of 
murine ABC transporters Bcrp1, P-gp, and Mrp4 in CNS penetration of erlotinib and 
OSI-420. Furthermore, we used a panel of cell lines expressing human efflux or uptake 
transporters to investigate transport processes involved in CNS penetration and 
intracellular accumulation of erlotinib and OSI-420. 
 
 
2.2. MATERIALS AND METHODS 
 
 
2.2.1. Animals 
 
Animals used were wild-type FVB, Abcg2-/-, Mdr1a/b-/-, Abcc4-/-, and Mdr1a/b-/-
Abcg2-/- mice. All mice were on a FVB genetic background, 3-4 month old, females, and 
provided by Taconic (Hudson, NY; except Abcc4-/-, obtained at SJCRH). All animal 
studies were conducted using protocols and conditions approved by the Institutional 
Animal Care and Use Committee. 
 
 
2.2.2. Chemicals and reagents 
 
GF120918 was purchased from API (China). Erlotinib, OSI-420 analytical 
standards, and the internal standards for each compound used in the mass spectrometry 
assay were kindly provided by OSI pharmaceuticals (Uniondale, NY). 
2-Hydroxypropyl-β-cyclodextrin (HPBCD) was purchased from CTD, Inc. (High 
Springs, FL).  
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2.2.3. Cell lines 
 
The porcine kidney epithelial LLC-PK1 cell line and the L-MDR1 cell lines 
stably expressing human ABCB1 were cultured in DMEM, 10% fetal bovine serum, 
penicillin 100 U/ mL and streptomycin 100 µg/mL; all from Invitrogen (Carlsbad, CA). 
Saos2 cells containing pcDNA3.1 empty vector, ABCG2, or ABCC4 were maintained in 
DMEM containing 10% fetal bovine serum, penicillin (100 U/mL), streptomycin (100 
µg/mL), and G418 sulfate (500 µg/mL; Invitrogen). HEK-293 cells stably transfected 
with OCT1, OCT2 (Hayer-Zillgen et al., 2002), OAT1, OAT2, OAT3 (Tahara et al., 
2006), OCTN1, and OCTN2 (Nezu et al., 1999), along with pcDNA vector–transfected 
controls were cultured in DMEM supplemented with 10% fetal bovine serum and G418 
sulfate (400-800 µg/mL). 
 
 
2.2.4. Determination of erlotinib and OSI-420 protein binding in mouse plasma 
 
Erlotinib and OSI-420 were added to mouse plasma (Hiltop, Scottdale, PA) to 
make final erlotinib and OSI-420 concentrations of 1, 2, and 4 µg/mL. 200 uL of plasma 
were added to each well of a 96-well equilibrium dialysis plate (Harvard Apparatus, MA) 
and incubated on a rotator at 37°C. Samples were collected from plasma and PBS buffer 
chambers at several time points after starting the experiment. Samples were analyzed 
using a validated liquid chromatography/mass spectrometry (LC/MS) method (Zhao et 
al., 2003). Unbound fraction (fu) of either erlotinib or OSI-420 was calculated as follows: 
 
fu =
CPBS
CPlasma
 
 
where CPBS and CPlasma are the concentrations of erlotinib or OSI-420 in PBS and plasma, 
respectively. To compare the unbound fraction of erlotinib and OSI-420 in different 
strains, plasma was isolated from each strain and equilibrium dialysis was performed as 
previously described. 
 
 
2.2.5. Erlotinib and OSI-420 plasma pharmacokinetics 
 
A single erlotinib dose was administered to all five strains of mice (n = 8-13 mice 
per group). To administer erlotinib, TarcevaTM (OSI Pharmaceuticals, Uniondale, NY) 
tablets were pulverized and suspended in 0.2% carboxymethylcellulose and 0.05% 
Tween 20, for a final concentration of 5 mg/mL. The erlotinib suspension was 
administered at a dosage of 50 mg/kg by oral gavage. Plasma samples were taken by 
retro-orbital bleeding at 7 time points after drug administration (5 minutes, 0.5 hrs, 1, 2, 
6, 12, and 24 hours). At least four different animals contributed to each time point. Blood 
samples were centrifuged at 3000 rpm for 3 minutes. Plasma samples were immediately 
stored at -80°C till further analysis using liquid chromatography/tandem mass 
spectrometry (LC MS/MS) (Zhao et al., 2003). 
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2.2.6. Development of pharmacokinetic limited sampling models for erlotinib and 
OSI-420 
 
Data from the plasma pharmacokinetic experiment were analyzed with nonlinear 
mixed-effects modeling using the importance sampling EM algorithm in NONMEM VII 
(Beal and Sheiner, 1980). A model with one compartment for erlotinib and one 
compartment for OSI-420 and first-order conversion from erlotinib to OSI-420 and first-
order elimination of OSI-420 was used to fit the plasma concentration-time data. Models 
with first-order absorption, zero-order absorption and sequential zero-order and first-
order absorption were tested. The appropriate model was chosen based on objective 
function value (OFV) and inspection of goodness-of-fit plots. The estimated parameters 
included the duration of zero-order infusion (D1), first-order absorption rate constant (ka) 
apparent oral clearance of erlotinib (CLERL/F), apparent volume of distribution of 
erlotinib (VERL/F), apparent clearance of OSI-420 (CLOSI/FE), and apparent volume of 
distribution of OSI-420 (VOSI/FE), where F is the bioavailability and FE is the fraction of 
erlotinib converted to OSI-420. Inter-individual variability (IIV) terms were added to the 
CLERL/F, VERL/F, CLOSI/FE, and D1 parameters. IIV was modeled as a log-normal 
distribution and a proportional error model was used for residual variability. 
 
Data below the lower limit of quantitation of 1 ng/mL were included in the 
analysis with a likelihood-based approach using method M3 as previously described 
(Ahn et al., 2008). Each strain of mice was analyzed separately, and the model 
parameters were used to develop a limited sampling strategy using the D-optimality 
algorithm in ADAPT 5 (D'argenio et al., 2009). The limited sampling strategy consisted 
of three time points at which plasma samples could be drawn in each microdialysis 
experiment in order to estimate the plasma exposure using the population priors. 
 
 
2.2.7. In vitro probe recovery studies 
 
To study our ability to dialyze erlotinib and OSI-420 as well as strategies required 
to enhance their relative recovery through microdialysis probes, a stock solution 
containing 1 μg/mL erlotinib and 0.5 μg/mL OSI-420 in artificial CSF (aCSF, Leggas et 
al., 2004b) was prepared. A 1 mm microdialysis probe (MBR-1-5 brain probe, BASi, IN) 
was inserted into this solution and perfused with: (a) aCSF, (b) 10% HPBCD in aCSF, 
and (c) bovine serum albumin (BSA; 4% in aCSF) for 1 hour followed by 10% HPBCD 
in aCSF. To assess the effect of flow rate on the recovery of erlotinib and OSI-420 from 
the stock solution, perfusates were pumped through the probe at 0.3, 0.5, 1, and 2 μL/min 
and dialysates were collected. Dialysates and stock solution samples were analyzed using 
LC MS/MS. Relative recovery (%) was calculated as CDial/Cstock*100, where CDial is the 
erlotinib or OSI-420 concentration in the dialysates and Cstock is the erlotinib or OSI-420 
concentration in the stocks. All in vitro recovery experiments were performed at room 
temperature under stirred conditions.  
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2.2.8. Erlotinib brain microdialysis studies 
 
In vivo microdialysis experiments were conducted to sample erlotinib and 
OSI-420 in the ECF of the mouse brain after a single 50 mg/kg oral dose of erlotinib 
suspended in 0.2% carboxymethylcellulose and 0.05% Tween 20. First, a microdialysis 
guide cannula (MD-2255, Bioanalytical Systems- West Lafayette, IN) was inserted 
vertically into the striatum in the cerebral cortex (1.1 mm anterior to bregma suture, 1.1 
mm lateral to sagittal suture, 2.0 mm ventral). The surgery was performed under 
anesthesia (100 mg/kg ketamine and 10 mg/kg xylazine) as previously reported (Shen et 
al., 2009; Zhuang et al., 2006). Mice recovered for at least 3 days before the 
microdialysis experiment. The day of the experiment, a 1-mm-length microdialysis probe 
(MBR-1-5, BASi, IN) was primed and flushed with aCSF containing 10% HPBCD. The 
newly primed probe was then slowly inserted in the guide cannula and allowed to 
equilibrate for 1 hour at 0.5 µL/min. Under slight isoflurane anesthesia (2.5% in oxygen), 
the mouse received a 50 mg/kg dose of erlotinib, by oral gavage. Then, dialysates were 
collected for 24 hours, using a fraction collector CMA 142 (North Chelmsford, MA). 
 
We used the limited sampling strategy described above to collect plasma samples. 
At the end of the experiment, the animal was euthanized and the brain was fixed in 10% 
neutral buffered formalin for 72 hours and embedded in paraffin. H&E-stained sections 
(4 µm) were examined microscopically to examine the brain tissue surrounding the 
cannula and probe. 
 
 
2.2.9. In vivo microdialysis probe recovery using zero flow rate (ZFR) method 
 
After the first 5 hours of sample collection, dialysates were collected at different 
flow rates 0.2, 0.5, 1, and 4 µL/min. Dialysate concentrations were allowed to stabilize 
for 10-15 min between each change. The recovery experiment lasted 2.5 hours after 
which the flow rate was set back to 0.5 µL/min for the remainder of the experiment. 
Samples were analyzed using LC MS/MS and concentrations were plotted against flow 
rate. Extrapolation to zero flow rate was performed as previously described (Menacherry 
et al., 1992) using non-linear regression analysis in GraphPad Prism version 5.0b 
(GraphPad Software, San Diego, CA) using the following formula: 
 
CDial=C0*exp (-rA*X) 
 
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are 
constants, estimated using non-linear regression, C0 represents erlotinib or OSI-420 
concentrations in the dialyzed tissue, CDial is erlotinib or OSI-420 concentration in 
dialysates, and X is the flow rate at which the dialysate was obtained at different flow 
rates. Since the microdialysis experiment was performed at 0.5 µL/min perfusion rate, in 
vivo recovery was calculated as: CDial at 0.5 µL/min / C0 (Menacherry et al., 1992). 
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2.2.10. Pharmacokinetic analysis of microdialysis studies 
 
A pharmacokinetic model was fit simultaneously to the plasma and brain ECF 
microdialysis data. In order to incorporate information from the previous plasma 
pharmacokinetic experiment, pharmacokinetic data from both experiments was pooled 
and analyzed together. Modeling was performed with NONMEM VII using the 
importance sampling EM algorithm. The model was based on the model described above 
for plasma data, with additional compartments for erlotinib and OSI-420 in brain ECF. In 
addition to the previous parameters, this model included first-order rate constants 
describing erlotinib transfer into and out of the brain ECF (k24 and k42), first-order rate 
constants describing the transfer of OSI-420 into and out of the brain ECF (k35 and k53), 
and a single volume of distribution parameter for erlotinib and OSI-420 in the brain ECF 
(Vbrain). IIV was included on D1, CLERL/F, VERL/F, CLOSI/FE, VOSI/FE, and inter-
compartment rate parameters. 
 
Individual post-hoc parameters were used to simulate the concentration-time 
curve from 0 to 24 h in plasma and brain ECF for erlotinib and OSI-420 for each mouse 
from which the area under the concentration-time curves for plasma and brain 
(AUC0-24,Plasma and AUC0-24,Brain) were calculated with the log-linear trapezoidal method. 
Unbound plasma AUC (AUC0-24,uPlasma) for erlotinib and OSI-420 were obtained by 
multiplying AUC0-24,Plasma by the appropriate unbound fraction (fu). The extent of brain 
penetration (PBrain) for erlotinib and OSI-420 was calculated as the brain ECF-to-unbound 
plasma AUC ratio: 
 
୆ܲ୰ୟ୧୬ ൌ AUC଴ିଶସ,୆୰ୟ୧୬		AUC଴ିଶସ,୳୔୪ୟୱ୫ୟ 
 
Differences in PBrain between wild-type mice and other mouse strains were assessed using 
the Mann-Whitney test. 
 
 
2.2.11. Intracellular drug accumulation studies 
 
To study the role of several efflux and influx transporters in erlotinib intracellular 
accumulation, we used an array of cell lines expressing specific efflux or influx 
transporters and compared the accumulation of erlotinib or OSI-420 in the cell lines over-
expressing each transporter to that transfected with an empty vector. Intracellular 
accumulation of erlotinib and OSI-420 were measured in Saos2 cells transfected with 
human BCRP or MRP4 and LLC-PK1 cells transfected with MDR1, in presence or 
absence of the P-gp/BCRP inhibitor, elacridar. 
 
Uptake experiments were done using HEK293 cells transfected with cDNAs 
coding for members of human OCT, OAT, and OCTN families. Briefly, 5 x 105 cells of 
each cell line were plated in 6-well plates in triplicates. Cells were allowed to attach 
overnight. For cells expressing the OAT1, 2, 3, and their vector control, sodium butyrate 
(5 µmol/L) was added to the medium for 24 h to induce expression of the respective 
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transporter genes (Tahara et al., 2006). At the day of experiment, medium was removed 
and cells were incubated with media containing 0.5 µg/mL of either erlotinib or OSI-420 
at 37°C. At a predetermined time interval, the experiment was terminated by removing 
the incubation medium and adding ice-cold PBS. Cells were washed twice with ice-cold 
PBS, gently scraped, collected, and centrifuged for 4 minutes at 3000 rpm at 0°C. 
Subsequently, cells were resuspended in 100 µL of 5 mM ammonium formate for cell 
lysis. The BCA assay was used to determine protein concentrations. Erlotinib and 
OSI-420 concentrations in the lysis supernatants were determined using LC MS/MS 
(Zhao et al., 2003). 
 
 
2.3. RESULTS 
 
 
2.3.1. Erlotinib and OSI-420 protein binding in mouse plasma 
 
Using equilibrium dialysis, we assessed the extent of plasma protein binding for 
erlotinib and OSI-420. The range of concentrations used was similar to those expected 
after administering erlotinib orally to mice at 20 mg/kg. The time after which the dialysis 
reached equilibrium was 10 hours. Erlotinib, as well as its metabolite, was found to be 
highly protein bound in mouse plasma. Unbound fraction (fu) of erlotinib was 4.8% ± 
0.7% and for OSI-420 was 6.6 % ± 0.7%. No significant differences were found in 
unbound fractions of erlotinib or OSI-420 between strains (Table 2-1). 
 
 
2.3.2. Limited sampling models for erlotinib and OSI-420 
 
The erlotinib dosage used in preclinical studies has ranged from 5 to 150 
mg/kg/day orally for up to 4 weeks (Marchetti et al., 2008; Sarkaria et al., 2007). In our 
studies, we sought to use an erlotinib dosage that achieves a systemic exposure similar to 
that observed in patients (Broniscer et al., 2009; Broniscer et al., 2007b). First, we 
conducted a plasma pharmacokinetic study of a single erlotinib dose administered orally 
at a dosage of 50 mg/kg in wild-type, Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/-, and Abcc4-
/- mice. This single dose of erlotinib was tolerated well by all strains. 
 
Between the different absorption models, a sequential zero-order and first-order 
model described the data best based on goodness-of-fit plots and lowered the OFV 
between 6 and 35 units for different strains compared to first-order absorption alone and 
lowered the OFV between 9 and 33 units for different strains for zero-order absorption 
alone. The final model is shown in Figure 2-1. Concentration-time plots for erlotinib, 
OSI-420, along with the model-predicted concentrations are shown in Figure 2-2 and 
Figure 2-3. Pharmacokinetic parameters for all strains are listed in Table 2-2. 
 
The AUC0-24,Plasma in each strain was compared to wild-type mice. Mean 
AUC0-24,Plasma for Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/-, and Abcc4-/- strains were 1.25, 
0.9, 1.3, 0.9 fold compared to that of wild-type mice. Using the population parameters, 
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Table 2-1. Unbound fractions (fu) in plasma of different mouse strains 
 
Strain Erlotinib (fu) OSI-420 (fu) 
Wild-type 5.24 ± 0.8 7.47 ± 1.75 
Abcg2-/- 4.86 ± 0.1 8.08 ± 0.13 
Mdr1a/b-/- 5.59 ± 1.7 8.46 ± 0.91 
Mdr1a/b-/-Abcg2-/- 4.47 ± 0.09 7.33 ± 0.40 
Abcc4-/- 4.58 ± 0.49 7.12 ± 0.41 
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Figure 2-1. Compartmental pharmacokinetic model for erlotinib and OSI-420 
 
D1, duration of zero-order absorption; ka, first-order absorption rate constant; VERL/F, 
apparent volume of distribution of erlotinib; CLERL/F, apparent clearance of erlotinib; 
VOSI/FE, apparent volume of distribution of OSI-420; CLOSI/FE, apparent clearance of 
OSI-420; k24/k42, first-order rate constants of erlotinib in the brain extracellular fluid; 
k35/k53 , first-order rate constants of OSI-420 in the brain extracellular fluid; VBrain, 
apparent volume of distribution of the brain extracellular fluid. 
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Figure 2-2. Plasma concentration-time plots of erlotinib and OSI-420 after oral 
administration of a single dose of 50 mg/kg erlotinib 
 
Model-fitted curves are represented for erlotinib (solid line) and OSI-420 (dashed line). 
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Figure 2-3. Plasma concentration-time plots on linear scale of erlotinib and 
OSI-420 after oral administration of a single dose of 50 mg/kg erlotinib 
 
Model-fitted curves are represented for erlotinib (solid line) and OSI-420 (dashed line). 
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Table 2-2. Pharmacokinetic parameters for different mice strains 
 
PK parameters WT Abcg2-/- Mdr1a/b-/- Mdr1a/b-/-Abcg2-/- Abcc4-/-
Model Parameters 
(Unit)  
D1 (hr-1) 2.74 0.6 0.82 2.33 0.806 
Ka (hr-1) 0.21 0.049 0.19 0.12 0.202 
CLERL/F (L.hr-1.Kg-1) 0.56 0.51 1.1 0.75 0.67 
VERL/F (L. Kg-1) 0.006 0.0045 0.0009 0.021 0.0167 
CLOSI/FE (L.hr-1.Kg-1) 1.07 0.95 1.5 0.549 2.14 
VOSI/FE (L. Kg-1) 0.02 0.125 0.8 0.056 0.001 
k24 (hr-1) 10 0.037 8.22 0.694 9.84 
K42 (hr-1) 5.03 3.7 4.18 1.92 2.7 
K35 (hr-1) 0.079 0.082 0.11 0.004 0.1 
K53 (hr-1) 0.359 0.304 0.57 0.1 0.15 
Inter-individual variability (%CV) 
D1 67.5 2.9 71.0 36.1 48.8 
CLERL/F 43.4 2.5 56.8 9.6 89.5 
VERL/F 36 43.2 48.2 72 44.6 
CLOSI/FE 45.6 34.3 50.5 5 37.1 
VOSI/FE 21.5 70.3 77.4 60.7 40.1 
k24 27.6 27.5 29.8 28.2 91.9 
K42 31.2 11.2 44.7 42.3 66.7 
K35 16.7 21.8 19.6 50.7 71.2 
K53 26.9 31.9 3.6 33.7 46.7 
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Table 2‐2. (continued) 
 
PK parameters WT Abcg2-/- Mdr1a/b-/- Mdr1a/b-/-Abcg2-/- Abcc4-/-
 
Residual Error (%CV) 
Erlotinib 64.8 59.8 63.2 68 54.9 
OSI-420 65.5 60.6 62.7 66.8 53.5 
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we determined the optimal sampling time points to calculate the plasma AUC of erlotinib 
and OSI-420, constraining to three time points over 18 h. The optimal time points were 
similar in all strains: one early time point after the administration (5 min), one coinciding 
with the plateau (range from 7.8 to 9 hours), and one late time point (18 hours). For the 
ease of conducting the experiments, we chose to obtain plasma samples at 0.08, 8, and 18 
hours from all strains. 
 
 
2.3.3. In vitro microdialysis studies 
 
Because reproducible dialysis of lipophilic drugs can be difficult using 
conventional microdialysis methods (Loos et al., 2007; Wang et al., 2008), we anticipated 
that the microdialysis of erlotinib would require the inclusion of an affinity-based 
trapping agent, such as HPBCD, in the perfusate. Such modifications in the perfusate 
have been used before to increase the recovery of poorly dialyzable drugs (Duo et al., 
2006). Results of our preliminary in vitro microdialysis experiments supported that 
erlotinib and OSI-420 had relatively low relative recovery (1 and 2%, respectively) using 
aCSF as a perfusate. The addition of 10% HPBCD in aCSF improved the recovery of 
erlotinib and OSI-420 by ~ 8-fold (Figure 2-4). 
 
Second, we tested the effect of different flow rates (0.3, 0.5, 1, and 2 µL/min) on 
relative recovery. Increasing the flow rate yielded lower relative recovery. Lastly, we 
evaluated the effect of perfusing the microdialysis tubes with 4% BSA to prevent the 
binding of the drug to the tubes and thus improve the recovery. This strategy did not 
improve the relative recovery and added complexity due to tube blockage and flow 
resistance. Thus, we decided to use 10% HPBCD in aCSF at 0.5 µL/min at room 
temperature for the in vivo microdialysis experiments to obtain sufficient recovery with 
adequate sample volume (30 µL/h). The in vitro recovery at that flow rate was 18% ± 
2.5% and 20% ± 1.3% for erlotinib and OSI-420, respectively. 
 
 
2.3.4. Zero Flow Rate (ZFR) for estimation of in vivo recovery 
 
To calculate erlotinib and OSI-420 concentrations in brain ECF, microdialysate 
concentrations were corrected for probe recovery in each mouse using the ZFR method. 
This method is based on the fact that at slow perfusion rates and steady state tissue 
concentrations of the analyte, extrapolation to a hypothetical flow rate value of zero will 
provide the absolute value of analyte in the dialyzed tissue (CECF) (Jacobson et al., 1985). 
Probe recovery can then be calculated by dividing the concentration obtained at the flow 
rate at which the experiment is conducted (i.e., CDial at 0.5 µL/min) by CECF. First, we 
validated in vitro the use of the ZFR recovery method for recovery estimation. Dialysates 
were collected from a stock containing 1 µg/mL of each erlotinib and 0.5 µg/mL OSI-420 
at different flow rates and the concentrations were plotted against flow rate. The 
estimated value of CECF in vitro obtained from extrapolation to zero flow rate using non-
linear regression was 96%±15% and 93%±12% for erlotinib and OSI-420, respectively 
(results from 6 in vitro experiments; Figure 2-4). The ZFR requires that the concentration 
 
 
48 
 
 
 
Figure 2-4. In vitro microdialysis studies 
 
A. Including 10% HPBCD in the perfusate increases recovery for erlotinib and OSI-420 
as compared to aCSF alone. 
 
B. In vitro validation of the zero flow rate method. Erlotinib and OSI-420 stocks (1000 
and 500 ng/mL, respectively) were prepared; microdialysis probes were inserted in stocks 
and perfused with 10% HPBCD in aCSF. Dialysates were collected at different flow rates 
and concentrations were plotted against flow rate. CECF in vitro was estimated using non-
linear regression to a hypothetical zero flow rate. 
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remain relatively constant while collecting the dialysates at different flow rates. Initial 
microdialysis experiments (n=4) conducted under a stable flow rate of 0.5 µL/min 
showed that brain ECF concentrations dropped by only 10-15% over the 5 to 8 hr period. 
Assuming relatively stable target tissue concentrations, we decided to perform the 
recovery experiment after 5 hours from drug administration. After the recovery 
experiment, the flow rate was switched back to 0.5 µL/min and dialysates were collected 
up to 24 hours. The in vivo recovery for erlotinib was 39% ± 13% and for OSI-420 was 
24% ± 13%. 
 
 
2.3.5. Increased ECF penetration of erlotinib and OSI-420 in Abcg2-/- and Mdr1a/b-
/-Abcg2-/- mice 
 
Using microdialysis, we sampled brain ECF from wild-type, Abcg2-/-, Mdr1a/b-/-, 
Mdr1a/b-/-Abcg2-/-, and Abcc4-/- mouse strains after a single oral dose of erlotinib. Brain 
penetration ratios are shown in Figure 2-5. In wild-type mice, PBrain (mean ± SD) for 
erlotinib and OSI-420 was 0.27 ± 0.11 and 0.07 ± 0.02, respectively. Abcg2-/- mice 
showed 5-fold higher erlotinib penetration (1.4 ± 0.9, p < 0.05, n=5) and 7-fold higher 
OSI-420 penetration (0.51 ± 0.04, p < 0.05) than wild-type mice. However, neither 
erlotinib penetration (0.49 ± 0.3) nor OSI-420 penetration (0.04 ± 0.02) was enhanced in 
Mdr1a/b-/- mice (n=4, p > 0.05 for both). In the Mdr1a/b-/-Abcg2-/- mice, erlotinib brain 
penetration was 0.7 ± 0.26, ~3-fold higher than in wild-type mice (p < 0.01, n=5), and 
OSI-420 brain penetration (0.34 ± 0.21) was 4-fold higher (p < 0.01). Brain penetration 
of Abcc4-/- mice was similar to wild-type mice for both erlotinib (0.32 ± 0.24, p > 0.05, 
n=4) and OSI-420 (0.08 ± 0.06, p > 0.05). Histological examination verified the 
localization of the probe track in the brain ECF and indicated no bleeding due to probe 
insertion (Figure 2-6). 
 
 
2.3.6. Intracellular accumulation experiments 
 
Intracellular accumulation of erlotinib and OSI-420 was significantly reduced in 
Saos2-BCRP cells as compared to Saos2-pcDNA3.1, indicating the significant role of 
BCRP in erlotinib transport. Accumulation of OSI-420, but not erlotinib, in 
LLCPK1-MDR1 cells was significantly reduced as compared to controls (LLCPK1 
cells). Saos2-MRP4 cells did not show a significant difference in either erlotinib or 
OSI-420 accumulation (Figure 2-7). Pre-incubation for 30 minutes with the specific P-gp 
and BCRP inhibitor, elacridar significantly increased erlotinib and OSI-420 accumulation 
in Saos2-BCRP cells (p <0.01), and OSI-420 accumulation in LLCPK1-MDR1 cells (p 
<0.001) (Figure 2-8). 
 
Furthermore, we sought to determine whether erlotinib is a substrate for influx 
transporters using HEK-293 cells transfected with specific uptake transporters. Uptake of 
erlotinib and OSI-420 was significantly higher in presence of organic anion transporter-3 
(OAT3) (p <0.001) as compared to the HEK-293 cells transfected with empty vector. 
Additionally, expression of the organic cation transporter-2 (OCT2) significantly 
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Figure 2-5. Brain penetration of erlotinib and OSI-420 after a single oral dose of 
erlotinib 
 
A. Penetration of unbound erlotinib and OSI-420 to brain ECF expressed as PBrain (mean 
± SD from 4 to 7mice). *, P < 0.05 and **, P < 0.01, Mann–Whitney test of each 
knockout model compared with wild-type mice. 
 
B. Representative unbound erlotinib concentration-time plots in brain ECF (○) and 
plasma (▲) in wild-type, Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/- and Abcc4-/- mice. 
Model curves from individual predicted parameters are represented for plasma (dashed 
line) and brain ECF (solid line).  
 
 
51 
 
 
 
Figure 2-6. H&E staining showing the microdialysis cannula and probe track in 
brain ECF with no gross pathological effect of 10% HPBCD on brain tissue 
 
Blue dashes limit cannula track and red dashes limit probe track. 
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Figure 2-7. Erlotinib and OSI-420 intracellular accumulation in vitro in cell lines 
expressing efflux transporters 
 
Time-course of drug accumulation in cell lines. Control, cells lines transfected with an 
empty vector control; Transfected, cell lines transfected with a vector expressing the 
indicated transporter; Transfected + Elacridar, transporter-transfected cells treated with 4 
µM of the P-gp/BCRP inhibitor elacridar. Values are the percentage of the maximum 
accumulation (mean ± SD; n=4-6) in control cells (Saos2-pcDNA for BCRP and MRP4 
or LLC-PK1 for P-gp). 
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Figure 2-8. Intracellular accumulation data from 15 min and 30 min time-points 
combined 
 
*P < 0.001 as compared to accumulation in control cells (ANOVA with posthoc 
Dunnet’s test).  
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increased erlotinib and OSI-420 uptake (p <0.01) (Figure 2-9). 
 
 
2.4. DISCUSSION 
 
Using microdialysis sampling, transporter deficient mice, pharmacokinetic 
modeling, and cell lines transfected with efflux and uptake transporters, we elucidated the 
roles of transport mechanisms involved in erlotinib disposition in brain parenchyma. Our 
in vitro and in vivo data show that Bcrp1 is the primary efflux mechanism for erlotinib 
and OSI-420 at the murine BBB, whereas P-gp and Mrp4 have little or no effect on 
erlotinib CNS penetration. In vitro, intracellular accumulation of erlotinib and OSI-420 
showed that only OSI-420, not erlotinib, accumulation was reduced in cells 
overexpressing MDR1. The present study also showed that erlotinib and OSI-420 are 
substrates for the human organic uptake transporter OAT3 and, to a lesser extent, OCT2. 
 
Our technical approach of using microdialysis allowed the characterization of 
unbound (active) erlotinib concentrations in brain ECF. Our technique overcomes the 
limitations of (a) the CSF aspiration technique, which characterizes drug exposure in a 
very specialized CNS compartment (Shen et al., 2009), and (b) the whole brain 
homogenization technique, which does not discern between free and bound drug entities 
or between different CNS compartments (brain parenchyma, CSF, and brain vessels). Our 
study shows that the inclusion of HPBCD in the perfusate increases the recovery of 
erlotinib, probably by including the drug into the core of the HPBCD molecule (Khramov 
and Stenken, 1999b). 
 
Although HPBCD proved indispensable for the detection of erlotinib and OSI-420 
in the dialysate, its presence provided a challenge as we performed the recovery 
experiments. Because HPBCD forms inclusion complexes with erlotinib in the perfusate 
limiting drug movement to brain ECF, we could not use retrodialysis or no-net flux to 
estimate in vivo recovery values. Instead, we chose to use ZFR method to estimate 
recovery, realizing that as with all methods to calculate recovery, this approach has 
limitations. For example, the ZFR method should be applied when the target tissue (e.g., 
brain ECF) is at a steady state. Our initial microdialysis experiments (n=4) conducted 
under constant flow rate of 0.5 µL/min showed that brain ECF concentrations dropped by 
only ~12% over the 5 to 8 hour period. Thus, we assessed recovery during a period 5 to 8 
hours after the erlotinib dose was administered. 
 
Because we calculated the recovery during this time interval (i.e., 5 to 8 hours), 
we were only able to collect a single sample per flow rate. Although this short time frame 
may not have allowed adequate time to achieve stable recoveries at each flow rate, 
comparing in vitro recovery values obtained with either changing the flow rate or under 
constant (i.e., stable) flow rate yielded similar recovery values suggesting that stable 
recoveries can be achieved with our experimental approach (Table 2-3). 
 
Our study has established that penetration of unbound erlotinib from plasma
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Figure 2-9. Transport of erlotinib, A and OSI-420, B by human organic ion 
transporters 
 
Results are shown for drug accumulation in HEK293 cells after 5 minutes incubation in 
each cell line. Columns represent (mean ± SD) 8 to 18 observations per expressed 
transporter, and are expressed as percentage of their respective control (white bar). Only 
one control bar is shown for clarity purposes. The contribution of each transporter 
towards erlotinib or OSI-420 uptake was established by comparing data obtained in 
HEK293 cells overexpressing the transporter and HEK293 cells transfected with an 
empty vector.* P < 0.05; ** P < 0.01; *** P < 0.001 versus control, one-way ANOVA 
was performed followed by a post Dunnett test. 
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Table 2-3. In vitro recovery values (%) obtained while changing perfusion flow 
rates in a similar fashion to in vivo experiment to recoveries obtained with stable 
flow rate 
 
 
Similar recovery values shows ability to achieve stable recoveries during the ZFR 
recovery estimation in vivo.  
Flow rate 
(µl/min) 
Recovery (%) with changing flow 
rate 
(mean ± SD of 5 experiments) 
Recovery (%) with constant 
flow rate 
(mean ± SD of 4 experiments) 
0.2 28.1 ± 2.2 32 ± 3 
0.5 16.2 ± 1.9 18.5 ± 2 
1 5.36 ± 2.7 7.3 ± 1.2 
4 4.8 ± 1.4 4.2 ± 0.7 
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across the BBB of wild type mice is limited (27%) and even lower for OSI-420 (7%). 
Thus, even though OSI-420 exhibits anti-tumor activity (Meany et al., 2008; Moyer et al., 
1997), its low CNS penetration and systemic exposure (~10-20% that of erlotinib in 
humans) suggest a minor role for OSI-420 in erlotinib clinical activity in brain tumors 
(Broniscer et al., 2007b; Ling et al., 2006). 
 
Our data show that Bcrp1 is the major efflux transporter limiting penetration of 
erlotinib and OSI-420 into murine brain ECF. In vitro studies showed reduced erlotinib 
and OSI-420 accumulation in Saos2-BCRP cells. Interestingly, a single nucleotide 
polymorphism in the ABCG2 promoter that correlates with lower BCRP expression was 
associated with higher erlotinib plasma exposure, indicating the important role of BCRP 
in erlotinib disposition (Rudin et al., 2008). 
 
Our results contrast with the conclusions by Kodaira et al stating that P-gp is the 
major efflux transporter for erlotinib at the murine BBB (Kodaira et al., 2010). This 
discrepancy can be explained by the different experimental designs used in each study. In 
the latter study, the authors administered erlotinib via the jugular vein for 2 hours and 
then analyzed erlotinib concentration in brain homogenates. They compared erlotinib 
concentration in brain homogenates to that in plasma only at one time point (i.e., 2 
hours), and did not account for erlotinib plasma protein binding. This study design has 
several limitations. First, the homogenate technique could provide different results as it 
describes drug accumulation in the whole brain rather than in specific compartments, and 
second, relying on only one time point to determine the penetration ratio can mask the 
whole exposure profile for erlotinib in plasma as it provides only a “snap shot” of the 
penetration profile. In our study, we used the oral route for administering erlotinib to 
mimic the clinical situation. Our studies also took into consideration the plasma protein 
binding of both erlotinib and OSI-420. 
 
While intracellular accumulation experiments showed that OSI-420 is a P-gp 
substrate, OSI-420 brain penetration was not increased in Mdr1a/b-/- mice. This can be 
due to the compensatory upregulation of Bcrp1 in Mdr1a/b-/- mice resulting in increased 
overall drug efflux from the brain. Our group previously used semi-quantitative 
immunohistochemical analysis to show that Bcrp1 is expressed at a higher level in the 
brain of Mdr1a/b-/- mice than that in wild-type mice (Shen et al., 2009). This observation 
agrees with previous study that shows 3 fold higher Bcrp1 mRNA in Mdr1a/b-/- mice 
microvessels compared to wild-type mice (Cisternino et al., 2004). 
 
In vitro screening of uptake transporters using HEK-293 transfected cells 
identified erlotinib and OSI-420 as substrates for OAT3 and OCT2. The affinity of these 
transporters for both anionic and cationic molecules has been previously reported (Ahn et 
al., 2009; Arndt et al., 2001). While HEK-293/OCT2 cells showed significantly higher 
erlotinib uptake, OCT2 contribution towards erlotinib uptake should be cautiously 
interpreted given the ~40 fold higher expression of SLC22A2 gene, encoding OCT2, in 
these cells (Filipski et al., 2008). Studying erlotinib disposition in Oct2-deficient mice 
will clarify the affinity of OCT2 towards erlotinib. 
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Our results could have clinical significance as Oat3 localized at the apical border 
of the choroid plexus can restrict the penetration of its substrates in the CSF (Nagata et 
al., 2002). Our group previously demonstrated that Bcrp1 and P-gp, localized apically at 
the choroid plexus, pump their substrate, topotecan, in the CSF (Shen et al., 2009; 
Zhuang et al., 2006). Thus, Oat3 can oppose the transport direction of P-gp and Bcrp1 at 
the choroid plexus decreasing CSF drug accumulation. In rodents, Oat3 is predominantly 
expressed at the basolateral border of brain endothelial cells where it has been implicated 
in the brain to blood transport of its substrates (Kikuchi et al., 2003; Mori et al., 2003). 
Further, OCT2 is expressed at the apical border of the endothelial cells and was shown to 
increase the brain accumulation of their substrates (Lin et al., 2010). 
 
Thus, in absence of Bcrp1 (i.e., in Abcg2-/- or Mdr1a/b-/-Abcg2-/- mice), the net 
erlotinib ECF accumulation would be determined by the net effect of factors that favor or 
oppose brain ECF penetration. Factors that favor erlotinib accumulation in the ECF 
include OCT2 at the BBB and lack of Bcrp1 at the BBB (Figure 2-10). On the other 
hand, Oat3 at the BBB and P-gp at the choroid plexus may restrict erlotinib accumulation 
in brain ECF by moving the drug from the brain to the blood or the CSF as schematized 
in Figure 2-10. This may explain the more than unity ECF accumulation for ABC 
transporters substrates in Abcg2-/- and Mdr1a/b -/-Abcg2-/- mice observed in our study and 
others (Kodaira et al., 2010; Kusuhara and Sugiyama, 2005; Lassman et al., 2005). 
Another transporter of potential interest is the organic anion transporting polypeptide 
(OATP2). OATP2 is expressed on both the apical and basolateral membranes of brain 
endothelial cells and probably mediates the accumulation of its substrates across the 
intact BBB vessels (Bronger et al., 2005; Gao et al., 1999; Kusuhara and Sugiyama, 
2005). Further studies are warranted to identify the role of uptake transporters in erlotinib 
CNS penetration. 
 
Regarding the implications of our results on erlotinib elimination, OCT2 and 
OAT3 transporters are abundantly expressed in the kidney (Bleasby et al., 2006). These 
transporters may explain the renal clearance component of erlotinib elimination, which 
accounts for ~10% of the overall elimination (Ling et al., 2006). However, transporters 
expressed in the liver such as OAT2 and OCT1 were not found to transport erlotinib 
indicating the involvement of other transport mechanisms such as OATP1B1 and 
OAT1B3. 
 
In conclusion, erlotinib is a Bcrp1 substrate whereas its metabolite is a substrate 
for both P-gp and Bcrp1. Erlotinib brain ECF accumulation was restricted mainly by 
Bcrp1. Intracellular accumulation studies confirmed the role of BCRP in erlotinib efflux 
and the dual P-gp/BCRP inhibitor, elacridar, increased erlotinib accumulation in cells in 
vitro. This study also indicates that erlotinib and OSI-420 are substrates for the uptake 
transporters OAT3 and OCT2. Further study is warranted to assess the role of these 
transporters in erlotinib brain accumulation. Our future experiments will focus on 
studying the effect of ABC transporter inhibitors on erlotinib penetration in high-grade 
glioma using genetically engineered animal models that recapitulate the genetics, the 
biology, and the histology of human tumors.
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Figure 2-10. Proposed model for the role of efflux and uptake transporters in erlotinib CNS penetration 
 
A. Schematic diagram for endothelial cells with transporters localized on either apical border (facing blood) or basolateral 
border (facing brain ECF). 
 
B. Schematic diagram for the choroid plexus forming the BCSFB. Transporters are localized on either the apical border (facing 
CSF) or basolateral border (facing blood). The arrows represent the direction of drug transporter.  
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CHAPTER 3.    MAGNETIC RESONANCE IMAGING (MRI)-GUIDED 
MICRODIALYSIS CANNULA IMPLANTATION IN A SPONTANEOUS 
HIGH-GRADE GLIOMA MURINE MODEL* 
 
 
3.1. INTRODUCTION 
 
Cerebral microdialysis sampling is used to monitor CNS anti-cancer drug 
disposition in mouse models (Boschi and Scherrmann, 2000). This approach provides 
advantages over other sampling methods (e.g., whole tissue homogenization) including 
sampling from discrete anatomic compartments such as the brain extracellular fluid 
(ECF) or ventricular cerebrospinal fluid (vCSF) (Elmeliegy et al., 2011b; Shen et al., 
2009), sampling from normal brain or brain tumor tissue, and acquisition of unbound or 
pharmacologically active drug moieties(Chaurasia et al., 2007). Furthermore, 
microdialysis enables serial sampling from individual animals, thereby reducing the 
number of animals required for pharmacokinetic investigations (Pan et al., 2007). 
 
Microdialysis has been frequently employed in studying anti-cancer drug 
penetration within brain tumors, particularly high-grade gliomas (Blakeley et al., 2009; 
Carcaboso et al., 2010; Ma et al., 2003; Ma et al., 2001). These studies are most often 
performed using murine orthotopic xenograft models in which human glioma cells are 
stereotactically injected into a defined brain location and the microdialysis guide cannula 
is simultaneously implanted. Tumor tissue then develops and surrounds the cannula 
(Carcaboso et al., 2010; Ma et al., 2003; Ma et al., 2001). 
 
Although orthotopic tumor xenograft models are easy to use, relatively 
inexpensive, and reproducible, in many cases the genetics and histology of human tumors 
are not adequately recapitulated (Richmond and Su, 2008). In addition, the tumor 
microenvironment and host immune responses are likely altered in immune compromised 
mice, which diminish the ability of xenograft models to truly recapitulate the features 
observed in human tumors (Becher and Holland, 2006). 
 
In contrast, genetically engineered murine models (GEMMs) of brain tumors 
bestow many of the genetic and histological features of malignant human brain tumors 
(Becher and Holland, 2006). In general, these mouse models develop tumors 
spontaneously upon alteration of signaling pathways critical for the development of the 
specific tumor of interest (Becher and Holland, 2006; de Vries et al., 2009). Thus, 
molecular and other complex processes including specific contributions of the tissue 
microenvironment, such as tumor angiogenesis, can appropriately mimic human disease 
in these spontaneous tumor models. 
 
 
 
*Reprinted with permission. Elmeliegy MA et al. (2011) Magnetic resonance imaging-
guided microdialysis cannula implantation in a spontaneous high-grade glioma murine 
model. J Pharm Sci 100:4210-4214. 
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In GEMMs, heterogeneous tumor growth patterns and development of tumors in 
different brain regions pose several technical challenges to using these models for CNS 
pharmacokinetic investigations (de Vries et al., 2009). For example, a major challenge to 
using cerebral microdialysis to study anti-cancer drug penetration in tumors of GEMMs 
is the difficulty of acquiring stereotactic coordinates to accurately place a microdialysis 
cannula in the tumor. Traditionally, the coordinates of the intersection of the coronal and 
sagittal sutures (bregma point) are used as a reference point for the placement of the 
microdialysis cannula (Bert et al., 2004; Shen et al., 2009). However, this approach is not 
practical in GEMMs because the bregma does not appear on images derived by MRI, 
which is the imaging method used to identify the size and location of the spontaneously 
arising tumors in the brain. 
 
The objective of the current study was to use MRI imaging to identify a reference 
point for implanting microdialysis cannula in spontaneously arising tumors in a GEMM 
for high-grade glioma. The accuracy of cannula placement was verified by post-mortem 
MRI and histological examination. 
 
 
3.2. MATERIALS AND METHODS 
 
 
3.2.1. Animals 
 
Transgenic mice used in this study were previously described (Chow et al., 2011). 
Briefly, conditional deletion of Pten, Tp53, and Rb1 in Gfap-expressing cells was 
induced by I.P injection of tamoxifen (Sigma, St. Louis, MO) to GFAP-CreERTM; 
Ptenflox/flox;Tp53 flox/flox;Rb1flox/flox post-natal day 30 (P30) mice at a dosage of 9 mg/40 gm 
weight daily for 3 consecutive days. Mice were maintained on a 12 h light/dark cycle 
with free access to food and water. Mice developed tumors within 4 to 6 months. Other 
mouse strains (C57BL6 and CD1 athymic nude mice) were also used for validation of 
reference point studies. All animal studies were carried out in compliance with the 
Animal Care and Use Committee at St. Jude Children’s Research Hospital. 
 
 
3.2.3. Magnetic resonance angiography (MRA) 
 
MRA data were produced from a Bruker FL2D Time-of-Flight (TOF) protocol 
(TR 7.6 ms; TE 3.77 ms; Flip angle 90 degree). The raw data were acquired in the coronal 
plane followed by Maximum-Intensity Projection (MIP) reconstruction on a Siemens 
workstation using Syngo MR B15 software (Siemens, Erlangen, Germany). Image 
processing procedures were similar for both angiography and post-mortem MRI studies. 
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3.2.2. Magnetic resonance imaging (MRI) 
 
MRI exams were performed using a 7-Tesla Bruker Clinscan animal MRI scanner 
and a 4-channel phased-array surface coil (Bruker BioSpin MRI GmbH, Germany). 
Animals were anesthetized using isoflurane during data acquisition. Turbo Spin Echo 
protocols (TR 2000-2500 ms; TE 40 ms) were used to produce T2 weighted transverse 
images with slice thickness of 0.5 mm.  Turbo Gradient Spin Echo protocols (TR 2000 
ms; TE 40 ms; Flip angle 180 degree) were used to produce fast T2-weighted images in 
the coronal plane with slice thicknesses of 0.7 mm. For post-mortem MRI, the mouse 
heads were submerged in Fluorinert FC-770 liquid (3M, Belgium) and imaged by a TSE 
protocol with a rat head 4-channel phased-array surface coil. 
 
 
3.2.4. Stereotactic surgery for microdialysis cannula insertion 
 
The general surgical procedure has been previously described (Leggas et al., 
2004b). Briefly, a mouse was anesthetized with 50 mg/kg ketamine (Hospira, Inc., Lake 
Forest, IL) and 10mg/kg xylazine (VEDCO, St. Joseph, MO). The head of the mouse was 
fixed in position on a KOPF stereotactic apparatus (Tujunga, CA). A small incision on 
the scalp was made and the rostral rhinal vein was identified. 
 
Using MRI images, tumor coordinates were calculated using View-Dimensions 
tool in Syngo MR B15 software. A microdialysis guide cannula was implanted in the 
center of a tumor. The mouse was allowed to recover for 3–5 days. On the day of the 
microdialysis study, a microdialysis probe (MBR-1-5, Bioanalytical Systems) was 
inserted through the cannula. The probe was perfused with artificial cerebrospinal fluid 
(aCSF, Leggas et al., 2004b) at 0.5 μL/min, and the probe membrane was allowed to 
equilibrate for 1 hour before starting the microdialysis experiment. Microdialysis 
experiments were performed as previously described (Elmeliegy et al., 2011b). 
 
 
3.2.5. Histology 
 
At the end of the microdialysis experiment, the animal was euthanized and the 
brain was removed and fixed in 10% neutral buffered formalin for at least 24 hr. Cannula 
and probe were removed and the brain was sliced into sagittal sections around the 
location of the implanted cannula, dehydrated, cleared, and embedded in a paraffin block. 
Sections were cut on a microtome at 4 µm thickness and every tenth section was 
collected and stained with haematoxylin and eosin. All sections from a given block were 
examined microscopically to verify the accurate placement of the microdialysis probe via 
the track in the tumor.  
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3.3. RESULTS AND DISCUSSION 
 
 
3.3.1. Identification of the rostral rhinal vein as a correlative reference point 
 
Images of blood vessels of the mouse brain acquired using angiography revealed 
the presence of a large vein overlying the border between the olfactory bulb and the 
frontal lobe (Figure 3-1A and B). Using the mouse cerebral vasculature atlas (Dorr et al., 
2007), this vein was identified as the rostral rhinal vein, which is readily apparent to the 
unaided eye and traverses both the dorsal and ventral surfaces following the olfactory 
bulb/frontal lobe border (Figure 3-1C). The removal of skulls (n≥6 per strain used) 
confirmed that this vein overlies the border between the olfactory bulb and the frontal 
lobe. Thus, we designated our reference point as the intersection of the midline suture and 
the rostral rhinal vein on the mouse brain surface. This point correlated with the 
intersection between the midline and the olfactory bulb/frontal lobe border visualized on 
T2-weighted MRI images of the brain. The rostral rhinal vein was present in all mouse 
strains evaluated including C57BL6 and CD1 athymic nude. Anatomical dissection of 
these strains confirmed that this vein overlies the olfactory bulb/frontal lobe border, thus 
this method may be applied to target tumors in other mouse strains. 
 
 
3.3.2. Determination of tumor coordinates and confirmation of probe placement 
 
Tamoxifen injection induced Cre activity and spontaneous glioma formation in 
GFAP-CreERTM;Ptenflox/flox;Tp53flox/flox;Rb1flox/flox mice (Chow et al., 2011). Induced mice 
were monitored biweekly for tumor development by MRI using T2-weighted imaging 
beginning at P120. Tumors developed in several locations within the brain including the 
forebrain, midbrain, and the cerebellum. When a tumor was large enough for 
microdialysis cannula/probe implantation (around 2.5-4 mm in diameter), placement 
coordinates were determined using the View-Dimensions tool in Syngo MR B15 
software. The X and Y axes were determined using the transverse plane (Figure 3-2A) 
while the depth of implantation (Z-axis) was determined using the coronal plane (Figure 
3-2B). Post-mortem MRI (Figure 3-2C and D) and immunohistochemical examination 
(Figure 3-2E) confirmed targeted probe placement in all mice studied (n=6). Mice used 
in this study developed tumors that arose within several regions of the brain including the 
forebrain (33%), midbrain (50%), and the cerebellum (17 %). 
 
 
3.4. CONCLUSION 
 
It is a challenge to accurately place microdialysis cannulae in GEMMs that 
spontaneously develop brain tumors because the traditional reference point commonly 
used to derive stereotactic co-ordinates for cannula implantation, the bregma, is not 
visible by MRI. By using a combination of angiography and T2-weighted imaging by 
MRI, we identified the rostral rhinal vein as a reference point to derive coordinates for 
accurate placement of microdialysis cannula in tumors developing in several regions of 
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Figure 3-1. Presence of the rostral rhinal vein on the surface of a mouse brain 
 
A. Angiogram of a non-tumor bearing GFAP-CreERTM; Ptenflox/flox; Tp53flox/flox; 
Rb1flox/flox mouse showing a large vein across the olfactory bulb/frontal lobe border. 
 
B. Diagrammatic illustration of veins on mouse brain surface illustrating the rostral rhinal 
vein on the border between the olfactory bulb and the mouse brain frontal lobe. 
Reproduced with permission from (Dorr et al., 2007). 
 
C. Brain surface of a GFAP-CreERTM; Ptenflox/flox; Tp53flox/flox; Rb1flox/flox mouse. Lines 
indicate location of the rostral rhinal vein. 
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Figure 3-2. Derivation of MRI-guided stereotactic coordinates for cannula 
implantation in spontaneously arising brain tumors 
 
A. Transverse section on a T2-weighted MRI demonstrating a tumor in the left 
hippocampus. Tumor margins are enclosed by a dashed line. The intersection between the 
olfactory bulb/frontal lobe border and the midbrain was used as a reference point to 
determine the coordinates on the Y-axis (a) and the X-axis (b). 
 
B. Coronal section on a T2-weighted MRI for calculation of the depth coordinates, i.e. 
Z-axis (c). In the provided example, values for a, b, and c were 7.6, 3, and 1.3 mm, 
respectively. 
 
C and D. Post-mortem MRI showing track of the microdialysis probe in the tumor in the 
X and Y axes (red arrow), and on the Z-axis (yellow arrow). 
 
E. Hematoxylin and eosin staining confirming probe location in the targeted area (yellow 
dots limit tumor margins, blue dashes limit cannula track, and red dashes limit probe 
track; lines were drawn with Adobe Photoshop V11.0).  
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the mouse brain.  
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CHAPTER 4.    CEREBRAL MICRODIALYSIS FOR SIMULTANEOUS 
SAMPLING OF TWO TYROSINE KINASE INHIBITORS IN AN 
ORTHOTOPIC MOUSE MODEL OF GLIOMA 
 
 
4.1. INTRODUCTION 
 
Anti-cancer drug penetration within brain tumors can be assessed using different 
strategies including cerebral microdialysis (de Lange et al., 2000). This method provides 
several advantages over brain tissue or tumor homogenization, including a significant 
reduction in the number of animals required per study due to collection of multiple 
samples per subject. Other advantages include providing compartment-specific 
information about drug penetration and sampling of the unbound (pharmacologically 
active) form of the drug. Cerebral microdialysis involves sampling of the target tissue 
ECF (e.g., brain parenchyma, ventricular CSF, or tumor) via a semi-permeable probe 
(Brunner and Langer, 2006). Perfusing the probe with a solution that mimics the 
composition of the tissue ECF (i.e. perfusate) allows small molecules (e.g., anti-cancer 
drugs) in the tissue ECF to diffuse across the semi-permeable membrane down their 
concentration gradient. The collected samples (i.e. dialysates) can then be measured using 
various analytical methods. 
 
Microdialysis is commonly used to sample tissue ECF to assess the disposition of 
a single anti-cancer agent per experiment. However, emerging therapies for brain tumors 
include combining more than one targeted agent due to the highly resistant nature of 
some cerebral tumors such as malignant glioma (Fan and Weiss, 2010; Karpel-Massler et 
al., 2011; Krakstad and Chekenya, 2010). Thus, a robust method to sample multiple anti-
cancer agents simultaneously coupled with adequate analytical methods can prove useful 
in determining the penetration profile of multiple anti-cancer agents administered in 
combination. To our knowledge, the technical feasibility of simultaneous sampling of 
multiple anti-cancer agents via cerebral microdialysis has not yet been published. 
 
One major limitation of microdialysis is the difficulty of sampling lipophilic 
drugs (Benfeldt and Groth, 1998; Carneheim and Stahle, 1991). Such compounds are 
generally highly-protein bound and thus only a small fraction of these compounds is 
available for recovery through the microdialysis probe (Benfeldt and Groth, 1998). 
Lipophilic compounds also tend to adhere to the polymeric materials of the microdialysis 
probe and tubing. Such poor recovery represents a challenge against the use of 
microdialysis to study the disposition of these lipophilic agents (de Lange et al., 2000). 
Attempts to enhance recovery of lipophilic compounds involved adding BSA in the 
perfusate, which reduces drug adsorption to microdialysis tubings (Carneheim and Stahle, 
1991; Jensen et al., 2007). Despite the enhanced recovery, adding BSA can cause some 
analytical challenges in sample cleanup for drug analysis using liquid chromatography 
(Stenken et al., 2001). 
 
The use of HPBCD has been proposed as an alternative to BSA to enhance the 
recovery of lipophilic drugs (Duo et al., 2006; Khramov and Stenken, 1999a; b). We 
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previously reported improved recovery of erlotinib upon including 10% HPBCD in the 
perfusate (Elmeliegy et al., 2011b). In the present study, we tested whether addition of 
this compound could improve the recovery of another tyrosine kinase inhibitor, 
crenolanib (CP-868,596; AROG Pharmaceuticals). Crenolanib is an investigational drug 
that specifically and potently inhibits PDGFRα and PDGFRβ (Lewis et al., 2009). 
Currently, crenolanib is undergoing phase I trials for patients with either diffuse intrinsic 
pontine glioma (DIPG) or recurrent high-grade glioma (HGG). Understanding the 
penetration of crenolanib as a single agent and in combination with another tyrosine 
kinase inhibitor, erlotinib in murine models of glioma will provide further insights into 
the best use of these agents in regimens for treatment of brain tumors. 
 
We conducted in vitro experiments to determine the appropriate conditions to 
dialyze crenolanib and erlotinib, either alone or simultaneously. We then applied these 
conditions to study crenolanib and erlotinib penetration as single agents or when 
administered in combination in an orthotopic mouse model of glioblastoma. 
 
 
4.2. MATERIALS AND METHODS 
 
 
4.2.1. Chemicals and reagents 
 
Erlotinib and OSI-420 analytical standards, and their deuterated internal standard 
used in the mass spectrometry assay were provided by OSI pharmaceuticals (Uniondale, 
NY). HPBCD was purchased from CTD, Inc. (High Springs, FL). Crenolanib (CP868, 
596 freebase, and its deuterated internal standard were supplied by Pfizer, New London, 
Connecticut, USA). 
 
 
4.2.2. Liquid chromatography/tandem mass spectrometry (LC MS/MS) method for 
crenolanib determination in mouse plasma and CSF samples 
 
Crenolanib and its deuterated form as an internal standard (ISTD) were separated 
on a Pursuit 3µ Diphenyl column (Varian Inc., Lake Forest, CA; 50 x 2.0 mm) with a 
mobile phase consisting of acetonitrile/10mM formic acid = 85/15/0.1. Samples were 
processed using liquid-liquid extraction with t-butyl methyl ether. Extracted samples 
were dried by nitrogen gas and reconstituted with Acetonitrile/10mM formic acid = 
60/40/0.1. Detection was achieved by an API-5500 LC-MS/MS system (Applied 
Biosystems, Carlsbad, California). 
 
 
4.2.3 In vitro probe recovery 
 
To evaluate probe recovery of crenolanib and erlotinib, stock solutions containing 
30 ng/mL crenolanib, 30 ng/mL erlotinib, or 30 ng/mL of each in aCSF were prepared. A 
1 mm microdialysis probe (MBR-1-5 brain probe, BASi, West Lafayette, IN) was 
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inserted into each solution. The probe was perfused with: (a) aCSF or (b) 
10%HPBCD/aCSF at 0.5, 1, 2, and 4 μL/min flow rate. Drug concentrations in each set 
of dialysates and stock solution samples were analyzed using LC-MS/MS. 
Concentrations were plotted against flow rate and extrapolation to a hypothetical ZFR 
was performed as previously described (Menacherry et al., 1992) using non-linear 
regression analysis in GraphPad Prism (GraphPad Software, San Diego, CA) using the 
following formula: 
 
CDial=C0*exp (-rA*X) 
 
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are 
constants, estimated using non-linear regression, C0 represents drug concentrations in the 
dialysed tissue, CDial is drug concentration in dialysates, and X is the flow rate at which 
the dialysate was collected (Menacherry et al., 1992). 
 
We then sought to determine whether the retrodialysis method, illustrated in 
Figure 1-5, could be used to estimate probe recovery in presence of an affinity-based 
trapping agent (HPBCD) in the perfusate. Thus, we perfused the probe with 30 ng/mL 
crenolanib in 10% HPBCD/aCSF at 0.5 µL/min. The collected dialysate was then used to 
determine the percentage of drug lost from the probe according to the following equation: 
 
ܦݎݑ݃	݈݋ݏݐ	ሺ%ሻ ൌ 	ܥ݌݁ݎ݂ݑݏ݁݀ െ ܥܿ݋݈݈݁ܿݐ݁݀ܥ݌݁ݎ݂ݑݏ݁݀ 	ܺ	100 
 
where Cperfused is crenolanib concentration in the perfusing solution i.e. 30 ng/mL and 
Ccollected is crenolanib concentration measured in the collected dialysate. 
 
On a separate experiment, we determined the percentage of drug gained from 30 
ng/mL crenolanib stock solution when perfused with 10% HPBCD/aCSF at 0.5 µL/min 
according to the following equation: 
 
ܦݎݑ݃	݃ܽ݅݊݁݀	ሺ%ሻ ൌ 	 ܥ݈݀݅ܽܥݏݐ݋ܿ݇ 	ܺ	100 
 
where Cdial is crenolanib concentration in the dialysate collected at 0.5 µL/min and 
Cstock is crenolanib concentration in the stock solution, i.e. 30 ng/mL. 
 
 
4.2.4. Tumor lines 
 
Luciferase-labeled SJG2 glioma cell line was cultured in DMEM supplemented 
with 10% fetal bovine serum from Invitrogen (Carlsbad, CA). This cell line was 
generated from a 10-year old female diagnosed with malignant glioma at St. Jude 
Children’s Research Hospital (Memphis, TN). This tumor line has been modified to 
stably express firefly luciferase (Dickson et al., 2007). Luciferase-labeled SJG2 cell line 
was used to generate the cranial orthotopic tumor model.  
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4.2.5. SJG2 orthotopic tumor xenografts 
 
8–12 week old CD1 athymic nude mice (Charles River Laboratories, Wilmington, 
MA) were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. With the 
guidance of a mouse brain atlas (Paxinos and Franklin, 2001), 5x105 SJG2 cells 
suspended in 5 μL Matrigel (Becton Dickinson, Bedford, MA) were injected 
stereotactically (David Kopf Instruments, Tujunga, CA) into the right caudate putamen. 
A microdialysis guide cannula (MD-2255, Bioanalytical Systems, West Lafayette, IN) 
was stereotactically implanted at the same coordinates of the tumor. Tumor growth was 
monitored by bioluminescence (IVIS-100 imaging system, Xenogen, Alameda, CA 
(Szentirmai et al., 2006). Briefly, mice were injected intraperitoneally with 120 mg/kg 
D-luciferin firefly (potassium salt) (Caliper Lifesciences, Hopkinton, MA) and imaged 
under isoflurane anesthesia after 5 minutes. All animal studies were carried out in 
compliance with the Animal Care and Use Committee at St. Jude Children’s Research 
Hospital. 
 
 
4.2.6. Magnetic Resonance Imaging (MRI) 
 
MRI exams were performed as previously described (Elmeliegy et al., 2011a). 
Briefly, T2 weighted transverse images were generated with turbo spin echo (TSE) 
protocols for transverse images and turbo gradient protocols for coronal plane using a 
7-Tesla Bruker Clinscan (Bruker BioSpin MRI GmbH, Germany) from animals 
anesthetized using isoflurane (2-3%). Images were read on a Siemens workstation using 
Syngo MR B15 software (Siemens, Erlangen, Germany). 
 
 
4.2.7. Determination of crenolanib protein binding in mouse plasma 
 
Crenolanib was added to mouse plasma (Hiltop, Scottdale, PA) to make final 
concentrations of 250 and 500 ng/mL. Crenolanib-spiked plasma (200 µL) was added to 
each well of a 96-well equilibrium dialysis plate (Harvard Apparatus, MA) and incubated 
on a rotator at 37°C. Samples were collected from plasma and PBS buffer chambers at 
several time points after starting the experiment. Samples were analyzed using LC 
MS/MS. Unbound fraction (fu) of crenolanib was calculated as follows: 
 
݂u	 ൌ ܥPBS/ܥPlasma		
 
where CPBS and CPlasma are the concentrations of crenolanib in PBS and plasma, 
respectively. 
 
 
4.2.8. Crenolanib and erlotinib steady state plasma pharmacokinetics 
 
For animals receiving crenolanib or erlotinib as single agents, a 30 mg/mL 
solution of either drug in DMSO was loaded in mini-osmotic pumps (Alzet, Model 
 
 
72 
2001D; Durect, Palo Alto, CA) and subcutaneously implanted in CD1 nude mice. For 
animals receiving both agents in combination, a solution containing 30 mg/mL of each 
crenolanib and erlotinib, was loaded in the mini-osmotic pumps with subsequent 
subcutaneous implantation. To determine the time required to achieve steady state, 
plasma samples were taken by retro-orbital bleeding at 5 time points after drug 
administration (3, 6, 12, 18, and 24 hours). At least three different animals contributed to 
each time point. Blood samples were centrifuged at 3000 rpm for 3 minutes. Plasma was 
immediately separated and stored at -80°C until further analysis using LC MS/MS. 
 
 
4.2.9. Cerebral Microdialysis 
 
Microdialysis experiments were performed in mice implanted with SJG2 cells 28 
to 42 days after tumor implantation in tumors whose bioluminescence signal was ≥ 108 
photons per second. On the day of the experiment, a microdialysis probe (MBR-1-5, 
Bioanalytical Systems, West Lafayette, IN) was inserted through the cannula and 
perfused at 0.5 μL/min flow rate with 10% HPBCD/aCSF. The probe membrane was 
allowed to equilibrate for 1 h. Under slight isoflurane anesthesia (2.5% in oxygen), mini-
osmotic pump loaded with crenolanib only, erlotinib only, or both, was then 
subcutaneously implanted. Dialysates were collected using a fraction collector CMA 142 
(North Chelmsford, MA) at four different flow rates of 0.5, 1, 2, and 4 μL/min. Dialysate 
concentrations were allowed to stabilize for 1 to 2 hours between each change. At least 
two samples were collected at each flow rate. Dialysates were collected 6-8 hours after 
pump implantation to ensure achievement of steady state in mouse plasma. Samples were 
then analyzed using a previously described LC MS/MS method for erlotinib (Elmeliegy 
et al., 2011b) and the above described LC MS/MS method for crenolanib. Erlotinib and 
crenolanib concentrations were plotted against flow rate. Extrapolation to a hypothetical 
ZFR was performed as previously described (Menacherry et al., 1992) using non-linear 
regression analysis in GraphPad Prism (GraphPad Software, San Diego, CA) using the 
following formula: 
 
CDial=C0*exp (-rA*X) 
 
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are 
constants, estimated using non-linear regression, C0 represents drug concentrations in the 
dialyzed tissue, CDial is drug concentration in dialysates, and X is the flow rate at which 
the dialysate was obtained at different flow rates. 
 
To ensure achievement of steady state in plasma, at least two plasma samples 
were obtained from each mouse during the microdialysis experiment. Unbound drug 
concentrations in plasma were obtained by multiplying total drug concentration by the 
appropriate unbound fraction (fu). The extent of tumor penetration (PTumor) was calculated 
as a ratio between steady state tumor ECF concentration to-unbound plasma 
concentration: 
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୲ܲ୳୫୭୰ ൌ ܶݑ݉݋ݎ	ܧܥܨୱୱ		݈ܲܽݏ݉ܽ	ܵܵ  
 
where Tumor ECFss is the C0 obtained from non-linear regression of dialysate 
concentrations obtained at different flow rates and Plasma SS is the average plasma 
concentrations obtained from each mouse. 
 
 
4.2.10. Statistics 
 
Data are presented as mean ± SD. Mann-Whitney test was used for non-paired 
comparisons of two groups of non-normally distributed data. 
 
 
4.3. RESULTS 
 
 
4.3.1. HPBCD improves crenolanib recovery in vitro 
 
Our previous experience with low probe recovery for erlotinib, a highly lipophilic 
agent, led us to include the affinity-based trapping agent HPBCD in the perfusate to 
improve crenolanib probe recovery, as crenolanib is also a highly lipophilic agent. In 
vitro microdialysis experiments showed that crenolanib had relatively low relative 
recovery of 12.2% ± 3.1% at 0.5 µL/min flow rate using aCSF as a perfusate. The 
addition of 10% HPBCD in aCSF improved the recovery of crenolanib by ~ 2.4-4.2-fold, 
depending on the flow rate (Table 4-1). Further, we tested the effect of different flow 
rates (0.5, 1, 2, and 4 µL/min) on relative recovery. Increasing the flow rate yielded lower 
relative recovery. Even with higher flow rates, crenolanib could be detected in all 
microdialysis samples. Binding of crenolanib to microdialysis tubing was slightly 
reduced when HPBCD was added to the perfusate (Table 4-2). Stock concentrations 
estimated using non-linear regression analysis were within ±15% accuracy of the starting 
concentration, indicating that ZFR was a suitable method for estimating probe recovery 
for crenolanib (Figure 4-1) (Menacherry et al., 1992). 
 
Retrodialysis method involves perfusing the probe with a known concentration of 
the analyte under the assumption that the diffusion process is quantitatively equal in both 
directions (i.e. percentage of drug lost from the probe = percentage of drug gained from 
the medium to the dialysate) (Figure 1-5) (Wang et al., 1993a). Thus, we performed in 
vitro microdialysis experiments to determine whether this assumption applies when 
affinity-based trapping agents such as HPBCD are included in the perfusate. Using 10% 
HPBCD/aCSF as a perfusate, the percentage of crenolanib lost was 3.2 ± 1.4 fold lower 
than that recovered from the stocks [Drug lost (%) << Drug gained (%)]. Thus, the basic 
assumption of retrodialysis method could not be verified using 10% HPBCD/aCSF 
perfusate. Since we could not use retrodialysis, we used the ZFR method, which should 
be applied at steady state conditions.  
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Table 4-1. In vitro recovery of crenolanib 
 
Flow rate (µL/min) aCSF 10% HPBCD/aCSF 
(Relative recovery %) 
Fold improvement 
0.5 12.2% ± 3.1% 52.4% ± 9.9% 4.2 
1 9.4% ± 1.5% 36.5% ± 22.5% 3.8 
2 8% ± 3.4% 19.3% ± 8.6% 2.4 
4 5.1% ± 1.3% 12.4% ± 6.8% 2.4 
 
Microdialysis probes were inserted in a 30 ng/mL stock solution of crenolanib and 
perfused aCSF or 10% HPBCD/aCSF. In vitro recovery values (%) were calculated as 
CDial/Cstock*100, where CDial and Cstock are crenolanib concentration in the dialysates and 
stocks, respectively. Data are reported as mean ± SD. Fold improvement was calculated 
the ratio between the mean recovery value using 10% HPBCD/aCSF and aCSF. 
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Table 4-2. Binding of crenolanib to microdialysis tubings 
 
Flow rate (µL/min) aCSF 10% HPBCD/aCSF 
(% bound to tubings) 
Fold reduction in 
drug binding 
1 46.1% ± 8.6% 23.7% ± 14.1% 1.94 
 
Stock solution of crenolanib (30 ng/mL) was prepared in aCSF or 10% HPBCD and 
pumped through the microdialysis tubings. Samples are collected and crenolanib 
concentrations in both the stocks and the collected samples are analyzed. Extent of 
crenolanib binding to the tubing (%) was calculated as: 
 
ܦݎݑ݃	ܤ݅݊݀݅݊݃	ݐ݋	ݐݑܾ݅݊݃	ሺ%ሻ ൌ 	ܥݏݐ݋ܿ݇ െ ܥܿ݋݈݈݁ܿݐ݁݀	ݏܽ݉݌݈݁ܥݏݐ݋ܿ݇ 	ܺ	100 
 
where Cstock is crenolanib concentration in the stock pumped in the tubings and 
Ccollected sample is crenolanib concentration in the sample coming from the other end 
of the tubings. Data are reported as mean ± SD of 3 observations at 1 μL/min. Drug 
binding was not significantly different between groups (P = 0.1, Mann-Whitney test), 
though there was a trend for reduced binding using 10% HPBCD/aCSF. Fold 
improvement was calculated as the ratio between the mean % drug bound using 10% 
aCSF and 10% HPBCD.  
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Figure 4-1. Validation of the ZFR method 
 
Crenolanib stocks (30ng/mL) were prepared; microdialysis probes were inserted in stocks 
and perfused with 10% HPBCD in aCSF. Dialysates were collected at different flow rates 
and relative recoveries (%) were plotted against flow rate. CECF in vitro was estimated 
using non-linear regression to a hypothetical zero flow rate to be 26.28 ng/mL (i.e. 
87.46% of the nominal concentration of 30 ng/mL).  
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4.3.2. Tumor growth kinetics and morphology 
 
We studied crenolanib and erlotinib penetration in an orthotopically implanted 
xenograft model of luciferase-labeled SJG2 glioma cells. The rate of engraftment of 
SJG2 cells in CD1 nude mice was 85% (30/35). SJG2 tumors grew as mildly infiltrative 
tumors invading through the brain parenchyma. These tumors were commonly associated 
with the development of ventricular edema (Figure 4-2A). SJG2 tumors reached the 
threshold bioluminescence signal, 108 photons per second, within 4-6 weeks post-
implantation (Figure 4-2B), and neurologic signs were observed within 5 weeks. 
 
 
4.3.3. Crenolanib and erlotinib steady state plasma pharmacokinetics 
 
Determining the time required to achieve steady state in vivo is important in 
designing the sampling strategy when using the ZFR method to calculate in vivo probe 
recovery. We conducted a plasma pharmacokinetic study of crenolanib only, erlotinib 
only, and crenolanib/erlotinib combination to determine the time required to reach steady 
state drug concentrations in mouse plasma. Mini-osmotic pumps loaded with crenolanib, 
erlotinib, or both agents in DMSO were subcutaneously implanted in CD1 nude mice at a 
target dosage of 200 mg/kg/day. The drug release rate from these pumps is 240 µg/hr for 
at least 24 hours. This dosage was well tolerated by the mice as visually observed by 
normal respiratory rate, ability of the animal to defecate/urinate, regular access to food 
and water, and absence of any neurological signs. Steady state levels of both crenolanib 
and erlotinib were achieved within 6 hours post-implantation and were maintained for at 
least 24 hours (Figure 4-3), as determined by comparing drug concentrations at 6 hours 
to that at 3 and 24 hours. Plasma levels at 6 hours were significantly higher than at 3 
hours (Mann-Whitney test, p < 0.05), but similar to that observed at 24 hours 
(Mann-Whitney test, p > 0.2; Figure 4-3). 
 
 
4.3.4. Crenolanib protein binding in mouse plasma 
 
Using equilibrium dialysis, we assessed the extent of crenolanib protein binding 
in mouse plasma. The concentrations used were similar to those expected after 
administering crenolanib to mice at 200 mg/kg using mini-osmotic pumps (i.e., 250 and 
500ng/mL). The time required to reach equilibrium was 18 hours. Crenolanib was found 
to be highly protein bound in mouse plasma. Unbound fraction (fu) of crenolanib was 
5.9% ± 0.5% and 6.1% ± 0.7% for the 250 and 500 ng/mL concentrations, respectively 
(Figure 4-4). 
 
 
4.3.5. Crenolanib penetration in SJG2 xenografts 
 
We used cerebral microdialysis to sample crenolanib penetration in an orthotopic 
mouse model of glioblastoma (i.e. SJG2). Crenolanib was administered as a single agent 
subcutaneously using mini-osmotic pumps (target dosage 200 mg/kg). Using 10%  
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Figure 4-2. Growth characteristics of SJG2 tumors 
 
A. T2-weighted MRI of two representative SJG2 tumors displaying invasive growth 
pattern through the normal brain parenchyma with ventricular edema. 
 
B. SJG2 tumor bioluminescence signal versus time. Data are presented as mean and SD 
of 4-10 values per time point. Representative bioluminescence pictures are shown. 
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Figure 4-3. Concentration-time profile for crenolanib, erlotinib, and OSI-420 
after implantation of mini-osmotic pumps in CD1 nude mice 
 
Concentrations obtained after single agent administration of crenolanib or erlotinib (red 
lines) were similar to that obtained after administering both agents in combination (blue 
lines) (p > 0.05). Steady state levels were achieved 6 hours post-implantation. Values for 
steady state concentrations are reported on figure in ng/mL as mean ± SD of values 
obtained at 6, 12, 18, and 24 hours.  
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Figure 4-4. Crenolanib is highly bound to plasma proteins 
 
Crenolanib plasma protein binding assessed using equilibrium dialysis at two 
concentrations (250 and 500 ng/mL). Unbound fraction (fu) was calculated as mean 
values from 18, 24, and 36 hours.  
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HPBCD/aCSF as perfusate and sensitive analytical methods, we were able to detect 
crenolanib in dialysates. The mean ± SD for crenolanib penetration in SJG2 tumors was 
PTumor= 0.19 ± 0.03, n=4 (Figure 4-5). 
 
A second cohort of mice received crenolanib and erlotinib in combination (target 
dosage of 200 mg/kg of each). Collected dialysates were split for analysis of crenolanib 
and erlotinib/OSI-420. Crenolanib penetration in mice receiving crenolanib and erlotinib 
(PTumor= 0.13 ± 0.05, n=6) was similar to that in mice receiving crenolanib alone 
(Mann-Whitney, P = 0.07; Figure 4-5). 
 
 
4.3.6. Erlotinib penetration in SJG2 xenografts 
 
Erlotinib was administered as a single agent using mini-osmotic pumps (target 
dosage 200 mg/kg). The mean ± SD of erlotinib penetration in SJG2 xenografts was 
PTumor= 0.25 ± 0.03 n=4 (Figure 4-5). For the combination group, mice received 200 
mg/kg of each crenolanib and erlotinib. In this group, erlotinib penetration (PTumor= 0.26 
± 0.06, mean ± SD, n=6) was similar to that in mice receiving erlotinib alone 
(Mann-Whitney, P = 0.47). OSI-420, the major erlotinib metabolite, was not detected in 
the dialysates in any of the tested groups (single agent or combination) (Figure 4-5). 
 
 
4.4. DISCUSSION 
 
Previous studies have reported irreproducible dialysis of lipophilic drugs 
(Lindberger et al., 2002; Loos et al., 2007; Wang et al., 2008). In addition, previous 
studies have only evaluated a single anti-cancer agent, an approach that has limited 
relevance in light of the prevalent use of combinations of two or more anti-cancer drugs 
in therapy. Here, we added the affinity-based trapping agent HPBCD to the perfusate to 
increase microdialysis probe recovery of two lipophilic anti-cancer drugs, crenolanib and 
erlotinib. We then used this method to determine crenolanib and erlotinib tumor 
penetration as single agents or when administered in combination. 
 
A major limitation of cerebral microdialysis is associated with the poor recovery 
of lipophilic compounds due to the tendency of these compounds to stick to the sampling 
probe and tubing components, poor solubility of these compounds in the hydrophilic 
perfusate, and their high protein binding affinity which limits the unbound drug in the 
sampling space (Benfeldt and Groth, 1998; Benveniste and Huttemeier, 1990; Carneheim 
and Stahle, 1991; de Lange et al., 2000; Lindberger et al., 2002; Oravcova et al., 1996). 
Several attempts to improve recovery of lipophilic compounds involved replacing the 
commonly used hydrophilic perfusates with hydrophobic solutions such as 2.25% 
glycerol in water or 20% soybean oil/ egg phospholipid (Intralipid®) which allow the 
lipophilic drug to accumulate in the perfusate (Carneheim and Stahle, 1991; Kurosaki et 
al., 1998). Other attempts involved adding BSA in the perfusate where the drug can bind 
to BSA rather than the sampling device (Carneheim and Stahle, 1991). While these 
approaches are often successful in improving the recovery of hydrophobic compounds,
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Figure 4-5. Crenolanib and erlotinib penetration in SJG2 xenografts 
 
Drugs were administered via mini-osmotic pumps. Tissue ECF was sampled via cerebral 
microdialysis using 10%HPBCD/aCSF perfusate and using the ZFR recovery approach. 
Mouse plasma samples were obtained via retro-orbital bleeding and corrected for protein 
binding. Extent of tumor penetration (PTumor) was expressed as the ratio between tissue 
concentration at hypothetical ZFR and unbound drug in mouse plasma. Tumor 
penetration of unbound crenolanib and erlotinib after single agent or combination 
administration of 200 mg/kg/day crenolanib, erlotinib, or both, via mini-osmotic pumps 
in SJG2 mice. No statistical difference was observed in drug penetration between single 
agent and combination groups, P > 0.05. Statistical analysis was performed using Mann 
Whitney test.  
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they add technical challenges during the experiment (i.e., flow resistance and tube 
blockage, as well as analytical challenges during sample cleanup for LC-MS/MS assays) 
(Elmeliegy et al., 2011b; Jensen et al., 2007; Sun and Stenken, 2003). 
 
Another approach is the use of cyclodextrins in the perfusate (Khramov and 
Stenken, 1999a; b). Cyclodextrins form complexes with lipophilic molecules by 
capturing them in a non-polar central cavity (Loftsson and Brewster, 1996). Upon 
including cyclodextrins in the perfusate, they form an inclusion complex with the analyte 
on the dialysate side of the membrane reducing the effective concentration of the analyte 
on the dialysate side. This results in a larger concentration gradient that facilitates more 
diffusion from the target tissue to the dialysate which leads to higher recovery (Khramov 
and Stenken, 1999a). Advantages of using HPBCD include its high safety profile (Gould 
and Scott, 2005) and that it can be directly injected on the HPLC minimizing sample 
processing prior to analysis (Italia et al., 1990; Maguire, 1987). 
 
While including HPBCD in the perfusate proved technically indispensable in our 
experiments, it also added some experimental challenges in estimating probe recovery. 
During recovery estimation, HPBCD can form inclusion complexes with the drug 
preventing its passage through the probe and thus all recovery estimation methods that 
involve perfusing the probe with drug solution, e.g. retrodialysis, cannot be used to 
estimate probe recovery should HPBCD be included in the perfusate. This mandates the 
use of other recovery methods that do not involve drug perfusion through the probe. 
These methods usually require constant drug concentrations while determining the 
recovery, such as ZFR method (Elmeliegy et al., 2011b). 
 
In vivo microdialysis experiments showed that crenolanib and erlotinib could be 
simultaneously dialyzed and detected in the dialysates. However, we could not detect 
OSI-420 in most of our microdialysis samples. We have previously reported that OSI-420 
exhibits low penetration profile to mice brains (~7%) (Elmeliegy et al., 2011b). Since 
average steady state concentrations of OSI-420 in mice plasma was 132 ng/mL (i.e. ~ 6 
ng/mL of unbound OSI-420 in plasma), therefore OSI-420 concentrations in the brain 
and that in the dialysates are expected to be below the LLOQ of our LC/MS-MS assay 
(0.5 ng/mL). 
 
We decided to use the steady state approach for dosing crenolanib and erlotinib 
for two reasons. First, the ZFR recovery method, employed in these experiments due to 
the presence of HBCD requires steady state drug levels at the target tissue. Second, 
crenolanib has a shorter half-life in mice (t1/2 of crenolanib in CD1 nude 
mice=0.53±0.11 hours, Dr. Clinton Stewart, unpublished data) than in humans (t1/2 of 
crenolanib=14±4.18 hours) (Lewis et al., 2009). Clinical trials of either crenolanib or 
erlotinib involve long-term chronic oral daily administration, which will result in steady 
state drug concentrations in patient plasma (Broniscer et al., 2007c; Lewis et al., 2009). 
Thus, studying CNS penetration of these drugs under steady state conditions in mice 
could provide better recapitulation of the clinical situation. 
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While the penetration of crenolanib to SJG2 tumors was similar between the 
single-agent and combination administrations, overall crenolanib tumor penetration was 
relatively low (PTumor=0.19 and 0.13), especially when compared to penetration of other 
compounds in mouse models of glioma (Agarwal et al., 2011a; Carcaboso et al., 2010; 
Vogelbaum et al., 2011; Wang et al., 2010; Zhou and Gallo, 2009). One possible 
explanation is the relatively high molecular weight of crenolanib, 601.72 Daltons, which 
may limit its passive diffusion through the BBB (Kniesel and Wolburg, 2000; Mahar 
Doan et al., 2002). Another potential explanation could be active crenolanib transport 
from brain to blood via efflux transporters at the endothelial cells of the BBB (Terasaki 
and Ohtsuki, 2005). Finally, an intact BBB in SJG2 xenograft model might also limit 
crenolanib penetration. 
 
Despite the relatively low penetration of crenolanib in SJG2 tumors (mean ± SD 
of crenolanib concentration in SJG2 tumors ECF was 2.55 ± 0.81 ng/mL n=4), PDGFRα 
phosphorylation was inhibited in 66% (2/3) of SJG2 tumors treated with crenolanib-
loaded mini-osmotic pumps for 24 hours (data not shown). While 2.55 ng/mL of 
crenolanib might be lower than crenolanib IC50 for PDGFRα determined using western 
blot experiments (8.1 ng/mL) (data not shown), our experimental methodology could not 
determine the concentration of free drug in the intracellular compartment. Given its high 
lipophilic nature, crenolanib might accumulate in the intracellular compartment in 
concentrations sufficient to inhibit PDGFRα activation. 
 
In conclusion, cerebral microdialysis can be used to simultaneously sample 
lipophilic anti-cancer agents. Inclusion of HPBCD increased probe recovery of 
crenolanib and erlotinib. Sensitive analytical techniques are needed for successful 
implementation of simultaneous sampling via cerebral microdialysis. This method will 
increase our ability to conduct CNS penetration studies for multiple anti-cancer drugs 
administered in combination.  
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CHAPTER 5.    SUMMARY, DISCUSSION AND FUTURE DIRECTIONS 
 
 
Primary CNS tumors, particularly malignant gliomas, represent a major 
therapeutic challenge to basic scientists and neuro-oncologists. Despite decades of 
research, hundreds of clinical trials, and aggressive treatment strategies, glioma patients 
still suffer from poor prognosis, poor quality of life, and low overall survival (Broniscer 
and Gajjar, 2004; Furnari et al., 2007; Wen and Kesari, 2008). Perhaps one of the most 
important reasons for this poor prognosis is the intrinsic resistance of malignant glioma 
achieved by effective DNA repair machinery (Frosina, 2009), deletion mutations in 
several tumor suppressor pathways such as P53 and RB pathways (Paugh et al., 2010b; 
TCGA, 2008), and simultaneous activation of multiple RTKs (Stommel et al., 2007; 
TCGA, 2008). These genetic abnormalities maintain glioma cell survival, proliferation, 
and stimulate its invasive growth pattern through the brain. 
 
Another reason for the clinically challenging nature of malignant glioma is the 
restricted delivery of anti-cancer agents to the active site in the brain, which is protected 
by several barrier systems such as the BBB and the BCSFB. The overall objective of this 
project was to better understand the CNS penetration of molecularly targeted agents 
currently in clinical trials for treatment of malignant glioma using mouse models of 
glioma. 
 
While microdialysis offers several technical advantages to understanding CNS 
drug penetration, it is not without limitations. One challenge to the use of microdialysis is 
the low probe recovery of lipophilic compounds. The low recovery of these compounds 
can be attributed to the tendency of these compounds to bind to the sampling 
components, their poor solubility in hydrophilic perfusates, their high protein binding 
affinity (which limits the unbound drug in the sampling space), and their tendency to 
accumulate in the intracellular compartment, which reduces the sampling pool in tumor 
ECF (Lindberger et al., 2002; Loos et al., 2007; Wang et al., 2008). This challenge is 
particularly significant because many of the compounds under development for treatment 
of brain tumors tend to exhibit lipophilic properties. 
 
To address this issue we chose to include an affinity-based trapping agent 
(HPBCD) in the perfusate to increase probe recovery of erlotinib and crenolanib, two 
highly lipophilic agents. This resulted in an eight- and four-fold increase in probe 
recovery for erlotinib and crenolanib, respectively. This approach has been successfully 
applied to enhance probe recovery of several lipophilic agents such as gefitinib, 
lapatanib, BEZ-235, and OSI-906 (data not shown). However, even with HPBCD in the 
perfusate, we could not detect sirolimus, an mTOR inhibitor, in dialysates obtained from 
U87-MG xenografts mouse models receiving 50 mg/kg sirolimus by oral gavage (data 
not shown). This may be explained by the large molecular weight of sirolimus (914 
Daltons), inability of HPBCD to form inclusion complex with sirolimus, or possibly due 
to low sirolimus penetration in these tumors. 
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While including HPBCD in the perfusate proved technically indispensable in our 
experiments, it also added experimental challenges. During recovery estimation, HPBCD 
forms inclusion complexes with the drug and thus recovery estimation methods that 
involve perfusing the probe with drug solution, such as retrodialysis, could not be used to 
estimate probe recovery. This mandates the use of other recovery methods (e.g., ZFR), 
which require a constant drug concentration in the target tissue (Elmeliegy et al., 2011b). 
 
Using HPBCD in the perfusate and the ZFR method for in vivo recovery 
estimation, we studied erlotinib and OSI-420 penetration in control and transporter-
deficient mice receiving erlotinib by oral gavage. We showed that Bcrp1 was the main 
efflux transporter restricting erlotinib and OSI-420 penetration in mouse brain. 
Intracellular accumulation studies confirmed the role of BCRP in erlotinib and OSI-420 
transport. Furthermore, we showed that OSI-420 is a P-gp substrate while erlotinib is not. 
OSI-420 is formed by removing one methyl group of erlotinib by CYP3A4. The different 
transport profiles of erlotinib and OSI-420 by P-gp suggests that even this slight 
structural difference between erlotinib and OSI-420 may affect the affinity of efflux 
transporters to their substrates (Elmeliegy et al., 2011b). 
 
BCRP and P-gp were shown to interact with several tyrosine kinase inhibitors. 
Both transporters are expressed on the endothelial cells forming the BBB, the epithelial 
cells of the choroid plexus forming the BCSFB, and on the glioma cell membrane. Thus, 
they can influence the disposition of their substrates in different CNS compartments (i.e., 
vCSF, brain ECF, or inside tumor cells). Further, these transporters are highly expressed 
in the small intestine and the colon and thus may reduce the oral bioavailability of their 
substrates (Lemos et al., 2008). 
 
While the contribution of efflux transporters to CNS disposition of anti-cancer 
drugs has been extensively studied, the role of solute carrier transporters in CNS and 
tumor cell uptake of anti-cancer agents remains unclear. We studied the intracellular 
accumulation of erlotinib and OSI-420 using an array of HEK293 cell lines that over 
express uptake transporters. Our data show that erlotinib and OSI-420 are substrates for 
OAT3 and OCT2. We are currently planning studies to determine the contribution of 
mouse Oct2 in erlotinib brain disposition using Oct2-/- murine models (Jonker et al., 
2003). Lower erlotinib accumulation in Oct2-/- mice would confirm the role of Oct2 in 
erlotinib transport and indicate the potential importance of this transporter. These studies 
can also provide further explanation for the high variability observed in erlotinib 
pharmacokinetics in patients. Immunohistochemical analysis of various uptake and efflux 
transporters will be conducted on mouse brain sections from wild-type and Oct2-/- mice to 
identify any compensatory changes in transporter expression in Oct2 deficient mice. 
 
We then sought to characterize erlotinib and crenolanib disposition in malignant 
glioma using cerebral microdialysis. We decided to use a transgenic mouse model of 
malignant glioma (conditional TKO) that highly recapitulates several features of the 
human disease including tumor histology and genetic profiles. However, one limitation 
against using these models in CNS penetration studies using cerebral microdialysis is the 
inability to identify the bregma point on MRI. Thus, we identified a new reference point 
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that relates the MRI scans to the mouse skull. This allowed accurate implantation of the 
microdialysis guide cannula using MRI-derived coordinates. 
 
Using this model, cerebral microdialysis studies to assess anti-cancer drug 
penetration in transgenic models where tumors arise spontaneously can be performed. 
This method can also be used to target catheters implanted stereotactically for local 
delivery of anti-cancer agents within brain tumors, a technique known as convection-
enhanced delivery. Convection-enhanced delivery involves insertion of a catheter directly 
in the tumor where drugs are then locally delivered through the implanted catheter under 
continuous pressure. This technique allows the delivery of high intratumoral drug 
concentrations while reducing systemic side effects. However, accurate catheter 
placement in the tumor is thought to be crucial for successful delivery of the anti-cancer 
agent. Inadequate placement of the catheter was shown to cause fluid accumulation in the 
subarachnoid space, which can be locally toxic. This is due to the high pressure required 
for delivery of the drug in the tumor (Valles et al., 2009). Given the high success rate of 
our method in identifying accurate stereotactic coordinates, our method can be applied to 
accurately target catheters used in convection-enhanced delivery of anti-cancer agents in 
novel preclinical models. 
 
The use of appropriate preclinical models that reflect the genetic and histological 
properties of the disease allows for better preclinical testing of novel anti-cancer agents. 
Both spontaneous and xenograft models provide a set of advantages and disadvantages to 
the research question. Spontaneous mouse models reproduce the microenvironment of 
high-grade glial tumors better than xenograft models (Becher and Holland, 2006; Chow 
and Baker, 2012; Kucherlapati, 2012). However, some concerns exist regarding the 
practical application of these models in pharmacokinetic investigations given the long 
latency for tumor development and the need for expensive imaging modalities to monitor 
tumor growth. Furthermore, tumors that arise spontaneously display greater heterogeneity 
compared to xenograft models. Indeed, we observed greater variability in tumor 
penetration and contrast enhancement in the conditional TKO model compared to SJG2 
xenografts (data not shown). This can be explained by the heterogeneous tumor growth 
pattern, location, and histological representation of the tumor in conditional TKO model 
while SJG2 tumors displayed more consistent growth pattern. 
 
We observed higher crenolanib penetration in the conditional TKO compared to 
that in SJG2 xenografts (data not shown). This may be explained by the contribution of 
uptake transporters to crenolanib transport. Additional studies are warranted to 
investigate the role of these transporters in crenolanib CNS disposition. Studies 
investigating the role of solute carrier transporters in crenolanib CNS penetration should 
study crenolanib intracellular accumulation in cell lines that overexpress uptake 
transporters. Finally, the role of a particular transporter identified in the initial screen 
should be further confirmed in mouse models deficient of that transporter. Identifying 
efflux and uptake transporters responsible for crenolanib transport may provide further 
explanation for the different crenolanib penetration profiles observed in transgenic and 
xenografts models. The vastly different crenolanib penetration profiles in conditional 
TKO and SJG2 xenografts indicates the importance of using more than one tumor model 
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in drug penetration studies. Different transporters expression and vascular properties 
among different models can drastically change drug penetration, and thus the use of a 
single model may be misleading. 
 
To achieve the required anti-tumor effect, tumor cells should be exposed to 
effective concentrations of the anti-cancer agent for a sufficient duration. It is important 
to emphasize that only the protein-unbound form at the active site is pharmacologically 
available to interact with its target and exert a pharmacological effect. Anti-cancer drug 
disposition within tumor compartments (vascular, extracellular, and intracellular) is 
controlled by intricate properties of each compartment (Figure 5-1). First, only unbound 
drug in plasma can diffuse across the BBB to accumulate within the tumor ECF. This 
process is restricted by tight junctions between endothelial cells of the BBB and an array 
of efflux and uptake transporters expressed on these cells. Unbound drug in tumor ECF 
can then accumulate inside tumor cells. However, intracellular drug accumulation can be 
influenced by efflux and uptake transporters expressed on glioma cell membranes 
(Carcaboso et al., 2010). Finally, non-specific binding of the drug in the intracellular 
compartment will further reduce the drug available to interact with its intracellular target 
(Figure 5-1) (Baselga, 2006; Hammarlund-Udenaes, 2010; Hammarlund-Udenaes et al., 
2008; Reichel, 2009). 
 
Unfortunately, methods for direct determination of unbound intracellular drug 
concentration are not available. However, future experiments should rely on combining 
several approaches to estimate unbound intracellular drug concentrations. Hammarlund-
Udenaes and colleagues elegantly proposed an equation that can be used to estimate 
unbound intracellular drug concentration in brain parenchyma (Hammarlund-Udenaes et 
al., 2008). This equation can be possibly applied to estimate unbound intracellular drug 
concentration inside tumor cells: 
 
ܥݑ, ݈݈ܿ݁ ൌ ܣݐݑ݉݋ݎ	ሺܸݑ, ݐݑ݉݋ݎ െ ܸݐݑ݉݋ݎ	ܧܥܨሻܸ݈݈ܿ݁	ܺ	ܸݑ, ݈݈ܿ݁	ܺ	ܸݑ, ݐݑ݉݋ݎ  
 
where Cu, cell is the unbound drug concentration in the intracellular compartment, 
Atumor is the total drug in tumor, Vu,tumor is the unbound drug volume of distribution 
in tumor (See text for explanation). Vtumor ECF and Vcell are the volumes of tumor 
ECF and tumor cells, respectively, and can be substituted by physiological values of the 
brain tissue and the astrocyte, respectively. Vu, cell is the volume of distribution of 
unbound drug in tumor cell. 
 
Vu, tumor describes the relation between Atumor and the unbound drug 
concentration in tumor ECF regardless of tumor to plasma concentration ratio. Vu, tumor 
can be calculated using the following equation: 
 
ܸݑ, ݐݑ݉݋ݎ ൌ 	ܣݐݑ݉݋ݎ െ ܣݒܽݏܿݑ݈ܽݎܥݑ, ܧܥܨ  
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Figure 5-1. Pharmacokinetic compartments of the CNS  
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where Avascular is the amount of drug in tumor blood vessels which can be estimated as 
previously described (Carcaboso et al., 2010) and Cu, ECF is the unbound drug 
concentration in tumor ECF obtained from microdialysis experiments. 
 
Atumor can be determined by tumor homogenization. We have previously used 
the term Vu, tumor to account for the shift in drug accumulation from the ECF to the 
intracellular compartment upon inhibiting efflux transporters (Carcaboso et al., 2010). 
We have previously combined microdialysis and tumor homogenization methods using 
steady state approach to determine Vu, tumor. Low Vu, tumor value indicates that the 
drug is more confined to the ECF compartment (i.e. high Cu, ECF) with less intracellular 
distribution while higher Vu, tumor value suggests that the drug exhibit more 
intracellular distribution (Carcaboso et al., 2010). However, Vu, tumor does not account 
for drug intracellular binding and thus cannot provide an estimate for the unbound drug 
concentration in tumor cells. Homogenate binding experiments can be used to determine 
the non-specific binding of the drug to the tumor. Determining intracellular binding will 
allow estimation of Vu,cell. Thus, future experiments should combine different sampling 
approaches (microdialysis, tumor homogenization, and homogenate binding) to estimate 
the unbound drug concentration in the intracellular compartment (Cu, cell). 
 
Several factors should be considered upon determining whether tumor penetration 
of an anti-cancer agent in preclinical models is “adequate” for testing in patients with 
malignant glioma. First, we should determine the unbound plasma systemic exposure that 
can be achieved and tolerated in patients enrolled in phase I trials. Second, we should try 
to recapitulate this exposure in preclinical models to determine whether the unbound drug 
concentrations achieved in the tumor at this exposure are effective to exert a 
pharmacological effect. 
 
Upon conducting these studies, the extent of tumor penetration should not be 
regarded as the only determinant of our decision on whether a certain agent is a good 
candidate for clinical testing. For example, a drug with high potency against its target can 
be effective despite its low tumor penetration. This is supported by our data that show 
66% inhibition of PDGFRα in SJG2 xenografts by crenolanib despite its relatively low 
tumor penetration in SJG2 xenografts. 
 
Furthermore, in vitro and preclinical testing of potential agents should be 
conducted at exposures similar to that achievable and tolerated in patients. Exerting a 
pharmacological effect only at exposures that are 10 fold higher than that clinically 
tolerated suggests a “no-go” decision for testing this drug in patients. In our experiments, 
steady state concentrations in mouse plasma were ~ two-fold lower compared to 
concentrations achieved in patients (Broniscer et al., 2009; Lewis et al., 2009). It is 
important to note that we could not increase the dose administered in our studies as we 
were limited by drug solubility in DMSO that was loaded in the mini-osmotic pumps. 
 
Despite PDGFRα inhibition by crenolanib, downstream signaling events (e.g., 
AKT phosphorylation was not affected) (data not shown). This agrees well with previous 
reports showing redundant signaling of multiple RTKs, such as PDGFR and EGFR, to 
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maintain active PI3K signaling in malignant glioma (Stommel et al., 2007). These studies 
indicate the need for combination regimens to inhibit PI3K pathway and alter glioma 
survival. Thus, we designed studies in which we combined PDGFR and EGFR inhibitors 
in our SJG2 xenografts and studied their tumor penetration using cerebral microdialysis. 
Using HPBCD in our perfusate, ZFR method to estimate in vivo probe recovery, and 
sensitive analytical techniques, we showed, for the first time, the feasibility of 
simultaneous sampling of multiple anti-cancer agents via cerebral microdialysis. Future 
studies should evaluate the effects of this combination on downstream Akt signaling at 
exposures achievable in the tumors. Our method will enable better understanding of CNS 
penetration of several drug combinations. Using our method, tumor penetration of several 
combinations targeting pathways known to maintain glioma survival should be evaluated. 
Such combinations may include agents that target multiple components of the same 
pathway (e.g., PDGFR, Akt, and mTOR inhibitors) or those targeting several pathways 
(e.g., PDGFR and MEK inhibitors). 
 
In conclusion, we developed new techniques to improve microdialysis probe 
recovery of erlotinib and crenolanib. We identified efflux and uptake transporters that 
regulate erlotinib CNS disposition. We developed an MRI-guided method to implant 
microdialysis cannula in a spontaneous glioma murine model. We identified suitable 
microdialysis conditions used to sample multiple anti-cancer agents in tumor ECF of 
mouse models of glioma.  
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